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INTRODUCTION 
 
Energy generation 
 
The adequate energy production is a crucial ability and necessity for any living 
cell. One of the elementary metabolic processes involved in energy generation is 
glycolysis. With variations, it occurs in many types of cells in nearly all organisms. Via 
glycolysis is energy in the form of energy-rich molecules (ATP) and electron carriers 
(NADH+H+) generated by oxidation of glucose to pyruvate (Champe, 2005). 
 In anaerobic conditions, pyruvate is converted by fermentation to waste 
products as lactic acid or ethanol and carbon dioxide. The final pyruvate conversion 
is important for the proper cell function, while it is the only process to remove 
hydrogens and electrons from the NADH+H+ and regenerate NAD+ (nicotinamide 
adenine dinucleotide) for another glycolysis to proceed. Lactate oxidation is 
especially important for human cells in the situations when glycolysis is the only 
source of ATP – during the fetal life period or later in severely-hypoxic conditions 
(Alberts, 1994; Hay, 2006; Champe, 2005; Makinde et al., 1998).  
In aerobic conditions in most eukaryotic cells, pyruvate is transported to the 
mitochondria, where it is converted by the pyruvate dehydrogenase complex to acetyl 
coenzyme A (acetyl-CoA) (Alberts, 1994; Champe, 2005). As a substrate, acetyl-CoA 
enters another series of enzyme-catalyzed chemical reactions - the citric acid cycle, 
also known as the Krebs cycle or the tricarboxylic acid cycle (TCA). Krebs cycle 
substrates do not come only from glycolysis, but also from beta-oxidation of fat acids 
and proteolysis (Champe, 2005). In all living cells, that use oxygen as a part of 
cellular respiration, Krebs cycle plays highly important role. For each acetyl group 
that enters the citric acid cycle, three molecules of NADH+H+ are produced. The 
Krebs cycle step of succinate oxidation to fumarate, catalyzed by succinate 
dehydrogenase, use flavin adenine nucleotide - FAD+ as the acceptor of electrons by 
forming FADH2 (Champe, 2005). All produced NADH+H+ and FADH2 donate 
electrons to the mitochondrial respiratory chain and ATP synthase processes called 
oxidative phosphorylation (OXPHOS) system (Kadenbach et al., 2000). Such an 
aerobic oxidation of carbohydrates, proteins, and fats connected with the efficient 
oxidative phosphorylation system, is markedly more efficient in generation of ATP 
than just glycolysis (Fontanesi et al., 2006). 
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 Mitochondria 
 
A mitochondrion is an organelle found in most of eukaryotic cells (Henze and 
Martin, 2003). Mitochondria are known as “powerhouses” of eukaryotic cells, 
because they generate most of the cell’s supply of the chemical energy source – of 
the ATP (Saraste, 1999). In addition to the metabolisms of proteins, fats, amino 
acids, porphyrins and many other substances, mitochondria are involved also in 
processes, such as signaling, cellular differentiation, cell death, controlling of the cell 
cycle and cell growth as well as in the aging process (McBride et al., 2006; Szibor 
and Holtz, 2003). 
Functional and phylogenetic studies of mitochondria clearly demonstrate their 
eubacterial origin (Chihade et al., 2000). Mitochondria are believed to be primeval 
interlopers, primitive bacteria that fostered an endosymbiotic relationship with early 
eukaryotic cells and eventually became integral to the normal function of those cells 
(McFarland et al., 2007). Mitochondria have themselves evolved and developed into 
highly specialized organelles with a key role in eukaryotic cell metabolism. Their 
primary function of energy conversion is indispensable to every eukaryotic cell. 
However, the relationship is reciprocal and mitochondria are critically reliant on the 
import of molecules from the cytosol for a variety of specialized purposes (McFarland 
et al., 2007). Mitochondria in largely postmitotic cells (e.g. cardiomyocytes, neurons 
or skeletal muscle cells) have a limited life span of a few weeks (Szibor and Holtz, 
2003). 
Mitochondria range from 1 to 10 micrometers in size (Vogel et al., 2006). As a 
cellular organelle, it consists of a continuous reticulum that makes up nearly 10% of 
the cell volume in respiring yeast cells (Yaffe, 1999). A double membrane, which 
encloses the organelle, creates two internal compartments (Frey and Mannella, 
2000). The space between the two membranes is called the intermembrane space 
and is interrupted by junction points in which the inner membrane and outer 
membrane are in contact. The volume enclosed within the inner membrane is known 
as the matrix compartment. In cells with high respiration rates, the inner membrane is 
convoluted; folding into tubular structures designated cristae (Cobine et al., 2006b). 
The cristae tubules are 30–40 nm in diameter (Frey and Mannella, 2000). The 
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mitochondrial reticulum is highly dynamic, constantly changing size and shape 
through fission and fusion events (Hermann and Shaw, 1998).  
The outer membrane is a relatively simple and presents barrier only for 
macromolecules. Therefore, it contains pore-forming proteins, which render it 
permeable to molecules up to few thousand Dalton (Vogel et al., 2006). Ions, nutrient 
molecules, ATP, ADP, etc. can pass easily through the outer membrane. 
The inner membrane is freely permeable only to oxygen, carbon dioxide, and 
water. For other components it presents highly efficient barrier and they must enter 
the matrix via special transporting proteins and systems. It is one of the most protein-
rich lipid bilayers in biological system containing various multisubunit protein 
complexes, which also perform several cell fundamental processes (Vogel et al., 
2006). The most abundant proteins are complexes of the OXPHOS. Over 80 different 
polypeptides interact on the inner mitochondrial membrane to form the respiratory 
chain (Chinnery and Turnbull, 2001). The rest of the inner membrane proteins are a 
specialized transporting proteins. 
The mitochondrial matrix houses plenty of enzymes involved in important 
processes of the metabolism of carbohydrates and fats, such as enzymes of the 
Krebs cycle and the β-oxidation.  
 
Fig. 1 Mitochondria  
a) scheme (inner membrane (IM), intermembrane space (IMS), outer membrane (OM) and 
matrix),(www.protein-ms.de/RES/Mito/mitoown.JPG); b) transmission electron microscopy in cultured 
human skin fibroblast, 40000x, (by the courtesy of Dr. Sládková); c) mitochondrial reticulum stained by 
MitoTracker Red, (by the courtesy of Dr. Sládková). 
 
 
a)    b)    c)     
 
 
The biochemistry of mitochondria has been the subject of intense investigation 
over the past 50 years (McBride et al., 2006; Yaffe, 1999). Within these organelles, 
not only sugars and long chain fatty acids are broken down, but also ADP is recycled 
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back into ATP, steroids and lipids are synthesized along with numerous other 
reactions that are essential for human life (McBride et al., 2006). 
A unique feature of mitochondria is the presence of a separate genome, 
mitochondrial DNA (mtDNA), which is distinct from that of the nucleus (Lee and 
Sokol, 2007). mtDNA is a circular double stranded molecule of 16 569 base pairs 
placed in the mitochondrial matrix. Genome encodes two ribosomal RNAs, 22 
transfer RNAs for protein synthesis and the 13 polypeptides (Szibor and Holtz, 2003). 
mtDNA does not have introns. Each mitochondrion contains several copies of mtDNA 
and every cell has many mitochondria, so there are hundreds of copies of mtDNA in 
one cell (polyplasmy). A human hepatocyte contains approximately 1000 copies of 
mtDNA (Lee and Sokol, 2007). However, mtDNA depends on nuclear genes for its 
enzymes of replication, transcription, translation and repair, including DNA 
polymerase γ, thymidine kinase 2, and deoxyguanosine kinase (Capps et al., 2003; 
DiMauro and Schon, 2003). Mitochondria rely upon the nucleus for all the other 
proteins involved in the many metabolic pathways that occur in this organelle 
(Leonard and Schapira, 2000).  
In mammals all functional mtDNAs are inherited from the mother so it presents 
maternal inheritance. Human mtDNA has a mutation rate 10-20 times higher that of 
nuclear DNA, probably due to failure of proof-reading by mtDNA polymerases 
(Finsterer, 2006). Normally all of an individual’s mtDNA is identical (homoplasmy). 
Occasionally, a sequence variation creates a dual population of wild-type and mutant 
mtDNA (heteroplasmy). It implies potentially harmful mutant mtDNA (Leonard and 
Schapira, 2000). Heteroplasmy is enhanced by the stochastic distribution of the 
mtDNA to daughter cells, resulting in changing mutation loads in consecutive 
generations and increasing the phenotypic variation of mitotic segregation. Because 
of mitotic segregation and polyploidy, phenotypic expression is dependent on a 
threshold effect. If the load of mutant mtDNA copies exceeds a certain amount, the 
effect of a mutation can no longer be compensated by the wild-type. mtDNA 
mutations include point mutations and small or large-scale rearrangements (deletions 
and duplications) (Zeviani and Di Donato, 2004). Since there are no introns, there are 
no splice-side mutations. Point mutations are commonly maternally inherited whilst 
deletions and duplications are most often sporadic. Disease expression is 
determined by the percentage of mutant mtDNA in a given cell or tissue, which may 
differ substantially among tissues (Lee and Sokol, 2007). The phenotypic variability is 
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also dependent on the pathogenicity of a mutation, the affected gene, its tissue 
distribution, and the dependency of an organ on the mitochondrial energy supply. 
Organs, such as the eyes, ears, central and peripheral nervous systems, heart, 
endocrine system, kidney, guts, and liver are commonly affected (Finsterer, 2006). 
Frequent fusion and fission within a dynamic network may be an efficient 
means of intermitochondrial DNA (mtDNA) complementation through exchange of 
genomes between fusing mitochondria (Nakada et al., 2001). Introduction of 
mitochondria bearing mtDNA mutations that inactivate cytochrome c oxidase (COX) 
into cells with wild-type mitochondria, resulted in dynamic mixing of matrix and 
membrane proteins, as well as mtDNA transfer, between normal- and COX-activity-
deficient organelles so that all mitochondria within the cell displayed comparable, 
high COX activity (Nakada et al., 2001). mtDNA is prone to mutations that 
accumulate in aging individuals (Nakada et al., 2001). Genetic complementation, 
likely achievable due to the dynamic network-like behavior, may represent a 
mechanism of repairing mtDNA mutations, and consequently maintain properly 
functioning oxidative complexes within the cell (Karbowski and Youle, 2003).  
 
Respiratory chain, oxidative phosphorylation and ATP synthesis 
 
The respiratory chain and OXPHOS system contains 83 polypeptides. 70 are 
encoded by nuclear genes; the other 13 are encoded by mtDNA (Leonard and 
Schapira, 2000). All together, they form of five multimeric protein complexes: 
Complex I – NADH:ubiquinone oxidoreductase (containing approximately 46 
subunits, 7 of them encoded by mtDNA) 
Complex II – succinate:ubiquinone oxidoreductase (4 subunits), which catalyze also 
the Krebs cycle step of succinate oxidation to fumarate 
Complex III – decylubiquinol-cytochrome c oxidoreductase (11 subunits, one of them 
encoded by mtDNA) 
Complex IV – cytochrome c oxidase (13 subunits, 3 of them encoded by mtDNA) 
ATP synthetase - complex V (approximately 16 subunits, 2 of them encoded by 
mtDNA), which is in fact an independent protein complex but its function is closely 
coupled to respiratory chain. Therefore some authors name it complex V and some 
authors strictly exclude this complex from respiratory chain complexes terminology. 
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Respiratory chain also requires two small electron carriers – ubiquinone 
(coenzyme Q10) and cytochrome c that shuttles electrons between large, relatively 
immobile macromolecular complexes imbedded in the membrane (Saraste, 1999). 
Each of these complexes incorporates multiple electron carriers. Complexes I, 
II, and III contain several Fe - S centers, while complexes III and IV include 
cytochromes (Wallace, 2001). 
 
Fig. 2 Creative drawing of the respiratory chain complexes. (Zeviani and Di Donato, 2004) 
Mitochondrially encoded subunits, embedded in the midst of nuclear-encoded subunits, are shown in 
different colors: complex I subunits = blue; complex III subunit = green; complex IV subunits = red; 
complex V subunits = yellow. Pi = inorganic phosphate; Cyt c = cytochrome c; CoQ = coenzyme Q.  
 
 
 
 
 
The mitochondria oxidize hydrogen to generate water and ATP. Reducing 
equivalents produced by the Krebs cycle and by β-oxidation are transferred to NAD+, 
generating NADH+H+, or to flavin adenine nucleotide (FAD+), generating FADH2. 
NADH+H+ donates electrons to respiratory chain complex I, whereas FADH2 cedes 
electrons, either from succinate (in the Krebs cycle) to complex II or from reduced 
electron transfer protein  (at the end of β-oxidation) directly to ubiquinone (coenzyme 
Q10). Ubiquinol transfers its electrons to complex III, where the electrons are picked 
up by cytochrome c. Cytochrome c brings the electrons to complex IV and finally the 
electrons are used together with ½ O2 to give rise of H2O molecule. The energy 
released by this process is used to pump protons (by complexes I, III and IV) from 
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the matrix to the intermembrane space, creating the transmembrane electrochemical 
gradient. The potential energy stored in the electrochemical gradient is used to 
condense ADP and inorganic phosphate to make ATP via complex V (ATP 
synthase), driven by the movement of protons back through a complex V proton 
channel (DiMauro et al., 2006; Fontanesi et al., 2006; Chinnery and DiMauro, 2005; 
Lee and Sokol, 2007; van den Heuvel and Smeitink, 2001; Wallace, 2001). Some of 
the physical energy of the proton gradient is used to generate heat. Produced ATP 
presents a readily utilizable and essential energy source for the eukaryotic cell 
(McFarland et al., 2007).  
The amount of energy released by oxidative phosphorylation is high, 
compared with the amount produced by anaerobic fermentation. Glycolysis produces 
only 2 ATP molecules, but almost 30 ATPs are produced by the oxidative 
phosphorylation of the 10 NADH and 2 succinate molecules made by converting one 
molecule of glucose to carbon dioxide and water (Rich, 2003). This ATP yield is the 
theoretical maximum value; in practice, some protons leak across the membrane, 
lowering the yield of ATP (Porter, 2001). 
The exclusive niche that mitochondria occupy in the metabolism of the 
eukaryotic cell is central to their role in human disease. The cells dependence on 
ATP derived from OXPHOS makes it extremely vulnerable to mitochondrial 
malfunction and even small reductions in the efficiency of ATP production in some 
tissues may have functional impact to the affected tissue. 
The OXPHOS system, which comprises the electron transport chain and ATP 
synthase, is the only cellular pathway under dual genetic control (DiMauro et al., 
2006). This fact can theoretically give rise to very variable symptoms, in any organ or 
tissue, at any age with any mode of inheritance (Munnich and Rustin, 2001). 
Additionally, dysfunction can originate from non-genetic causes as environmental 
influence (Munnich and Rustin, 2001). 
In the last few years, it has become increasingly clear that defects of oxidative 
phosphorylation account for a large variety of clinical symptoms in both childhood 
and adulthood. mtDNA deletions and mutations at least among pediatric cases 
account for not more than 10-15 % of patients (Leonard and Schapira, 2000). Thus, 
in most cases, nuclear gene defects are presumably responsible for respiratory chain 
deficiency. Disease-causing nuclear gene mutations fall in two categories: 1) 
mutations in nuclear-encoded respiratory chain subunits, and 2) mutations in 
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assembly and maintenance protein genes (Munnich and Rustin, 2001). Surprisingly, 
only a small number of catalytic subunit gene mutations have been reported (genes 
for complex II and complex I). Moreover, systematic sequence analysis of nuclear 
encoded subunits of complex IV has failed to detect any mutation in their coding 
sequences until this year (first case was reported by Zeviani M. et al. in March 2008 
at the MITOCOMBAT meeting). Taken together, these data support the view that 
mitochondrial assembly and maintenance are primarily altered in respiratory chain 
deficiencies (Munnich and Rustin, 2001).   
Mitochondrial disorders affect at least 1 in 5000 individuals (Schaefer et al., 
2004). Therapy of mitochondrial encephalomyopathies (as the defects of the 
mitochondrial respiratory chain are commonly named) is woefully inadequate, despite 
great progress during the past years in understanding of the molecular bases of 
these disorders. Palliative therapy is dictated by good medical practice and includes 
anticonvulsant medication, control of endocrine dysfunction, and surgical procedures 
(DiMauro and Mancuso, 2007; Zeviani and Di Donato, 2004). Lactic acidosis is one 
of the laboratory hallmarks of mitochondrial diseases. Pharmacological removal of 
this noxious metabolite extends to other metabolites as well (DiMauro et al., 2006). 
Administration of metabolites and cofactors is the mainstay of real-life therapy and is 
especially important in disorders due to primary deficiencies of specific compounds, 
such as carnitine or coenzyme Q10 (DiMauro and Mancuso, 2007). Aerobic exercise 
and physical therapy prevent or correct deconditioning and improve exercise 
tolerance in patients with mitochondrial myopathies due to mtDNA mutations 
(DiMauro and Mancuso, 2007). Gene and germline therapy is a challenge but it 
raises ethical problems. The accurate diagnosis is invaluable for the clinician and the 
patient, allowing prognostic and genetic counseling, and alerting the physician to 
potential complications in the future (Thorburn and Dahl, 2001). Even there is not a 
lack of treatment there is lack of cure, therefore preventive therapy through genetic 
counseling and prenatal diagnosis is highly important. The possibility of prenatal 
diagnostic is complicated by the dual origin of the mitochondrial proteins and is 
dependent on the knowledge of exact mutation in the affected family, while so far the 
proper prenatal diagnostic can be managed only in nuclearly encoded defects (Amiel 
et al., 2001; Faivre et al., 2000; Niers et al., 2003; Robinson, 2001).  
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COMPLEX IV – cytochrome c oxidase 
 
Cytochrome c oxidase (CcO; COX) is the terminal component of respiratory 
chain and is embedded in the inner mitochondrial membrane together with the other 
proteins of respiratory chain (Barrientos et al., 2002a; Taanman and Williams, 2001). 
It is a place where electrons end its pilgrimage through the respiratory chain 
enzymes to find its final acceptor. CcO accepts electrons from reduced cytochrome c 
and uses these to reduce molecular oxygen to water. At the same time, CcO 
contributes to the generation of the mitochondrial proton gradient by moving protons 
across the membrane (Kadenbach et al., 2000; Taanman and Williams, 2001).  
In mammals, CcO is present in the inner mitochondrial membrane as a large 
dimeric unit. Each monomer of the mammal protein consists of 13 subunits, similarly 
to 13 subunits found in the CcO from tuna (Arnold et al., 1997) and turkey 
(Kadenbach et al., 2000). Whereas, the CcO fulfils the same role in most of the 
organisms, the number of assembled subunits differs: 12 in yeast (Herrmann and 
Funes, 2005) or 7 in Dictiostelium discoideum (Kadenbach et al., 2000).  
The crystal structure of the bovine enzyme solved by (Tsukihara et al., 1996) 
allowed detailed insights into the three-dimensional organization of the complex (see 
fig.3) 
The three largest subunits, encoded by mtDNA, transcribed and translated in 
the mitochondrial matrix (Rodeheffer and Shadel, 2003), are the most evolutionary 
conserved (Ludwig et al., 2001). They form the core of the complex where the 
catalytic function relies on the redox-active catalytic cofactors including heme a and 
copper (Tsukihara et al., 1995, 1996). Subunit 1 (Cox1; COX I; CO I etc.) is the 
largest and most conserved one. It is composed of twelve transmembrane helices 
connected by short extramembrane loops and shows highly hydrophobic manners 
(Hermann and Shaw, 1998). Its catalytic function is connected to the protein 
translocation pathways (Stiburek et al., 2006) and to the two heme a moieties. The 
hemes are referred also as a and a3, based on the spin states of their iron atoms. It 
explains one of the traditional names of CcO - cytochrome aa3. Subunit 1 contains 
also one copper atom that form CuB site. Two other copper atoms form the binuclear 
CuA site of subunit 2 (Cox2; COX II; CO II etc.), which constitutes the docking site for 
cytochrome c (Stiburek et al., 2006). In addition, there is a magnesium ion occupying 
the cleft formed by subunits 1 and 2 (Tsukihara et al., 1995). Subunit 3 (Cox3; COX 
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III; CO III etc.) does not bear prosthetic group and its function is more in stabilization 
and correct functioning of the two others. 
 
Fig. 3. Crystal structure of the dimeric cytochrome c oxidase from bovine heart, as located in the inner 
mitochondrial membrane bilayer. (Kadenbach et al., 2000) 
On the cytosolic side, the crystal structure of a cytochrome c molecule (Cyt c) is shown in dark blue 
ribbons. Marked in yellow backbone are subunits I, II and III, the nuclear coded subunits are shown as 
ribbons in the indicated color. The hemes c, a, and a3 are indicated in black; the iron atoms in orange; 
and CuA and CuB in blue. On the left monomer, the chemical reaction is indicated schematically. On 
the right monomer, the nuclear-coded subunits are denoted, and the binding sites for the regulatory 
compounds ATP or ADP and 3,5-diiodothyronine (3,5-T2) are indicated. 
 
 
 
 
 
The remaining 10 subunits are encoded in the nuclear genome and, after 
translation on ribosomes in cytoplasm, they are imported into the matrix through the 
membrane transport proteins (TIM and TOM complexes) (Pfanner and Wiedemann, 
2002). Once imported, the nuclear-encoded subunits associate with the surfaces of 
subunits 1, 2, and 3 and form the CcO holoenzyme. These peripheral subunits have 
associated zinc and sodium ions, as well as several phospholipid molecules, but 
about their exact function is known very little.  
The nuclearly encoded subunit IV of the bovine heart enzyme contains two 
specific ATP binding sites. One located at the cytosolic domain (Napiwotzki and 
Kadenbach, 1998) and the other at the matrix domain (Arnold and Kadenbach, 1997) 
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(see fig.2). Recent studies show the effect of ATP bound from the cytosolic side on 
the decrease of the affinity to cytochrome c of the bovine heart enzyme (Napiwotzki 
and Kadenbach, 1998). The findings leaded to the second theory of controlling 
mechanism of respiratory chain activity known also as allosteric inhibition 
(Kadenbach et al., 2000; Ludwig et al., 2001). The subunit IV plays also a crucial role 
in assembly processes of the whole CcO (Li et al., 2006). 
Subunit Va contain a matrix side located specific binding place for 3,5-
diodothyronine. Filling of this site prevent the allosteric inhibition of activity by ATP 
(Arnold et al., 1998). This mechanism could explain the well-known short-term effect 
of thyroid hormones on the gene expression independent resting metabolism of 
animals (Kadenbach et al., 2000; Soboll, 1993). 
Protein kinase A binding site was located in the VIb subunit, which is located 
at the matrix site of the mitochondrial inner membrane (Yang et al., 1998). Its role in 
allosteric ATP-inhibition is connected with cAMP-depedent phosphorylation (Bender 
and Kadenbach, 2000). 
In mammals, subunit VIa is expressed in two tissue-specific isoforms – the 
VIaL is induced permanently and the VIaH is induced at high intramitochondrial 
ATP/ADP ratios (Grossman and Lomax, 1997). VIaH is expressed exclusively in 
heart and skeletal muscle of mammals, and depending on the intramitochondrial 
ATP/ADP ratio can regulate the H+/e- stoichiometry from 1,0 to 0,5 (Anthony et al., 
1993). The decrease probably participate in thermogenesis of mammalian skeletal 
muscle at rest when the ratio is high (Kadenbach et al., 1995). The VIaL isoform is 
expressed in all nonskeletal muscle tissues of mammals, where the H+/e- values are 
below 0,5 and are independent of the ATP/ADP ratios (Huttemann et al., 1999). 
Therefore, VIaL might participate in the permanent thermogenesis of warm-blooded 
mammals (Kadenbach et al., 2000).  
Similarly, the VIIaH isoform was found expressed in bovine heart and skeletal 
muscle, while in all other tissues, the VIIaL isoform was presented (Anthony et al., 
1990). The exact function of the two isoforms is unknown, as well as the function of 
specific isoforms of subunit VIII – VIIIH; VIIIL, which were found in bovine, dog and 
rat enzyme, whereas in human, sheep and rabbit is expressed only one of them 
(Kadenbach et al., 2000; Linder et al., 1995). 
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The function of the other nuclearly encoded subunits is still remaining almost 
unknown; it is believed they mainly participate in stabilization of the whole CcO 
enzyme. 
Over the years a great deal has been learned about the structure and 
arrangement of the subunits, but despite these advances, the manner, in which the 
enzyme is assembled in mitochondria, is still just partially understood (Fontanesi et 
al., 2006). 
The correct assembly of all CcO components in the right order to the exact 
position is clearly a multistep, complicated and well organized process. Over 30 
accessory nuclear-encoded proteins are involved. These auxiliary proteins play a key 
role in the formation of functional enzyme complex. The biogenesis of functional CcO 
enzyme occurs in several steps characterized by the formation of various assembly 
intermediates or subcomplexes (Nijtmans et al., 1998; Zee and Glerum, 2006).  
 
Scheme 1. Proposed model of the assembly pathway of human COX (Stiburek et al., 2005) 
The Arabic numerals denote subunits of the enzyme. S1–S4 indicate previously identified assembly 
intermediates. Prosthetic groups are also indicated. Dimerization of the 13-subunit holoenzyme 
(S4) completes the assembly of the COX complex. 
 
 
 
 
The biggest approach was done by studies with COX-deficient human cells, 
where the existence of three main assembly intermediates was suggested (Nijtmans 
et al., 1998; Stiburek et al., 2005). In both yeast and humans, the three 
mitochondrially encoded subunits are transcribed and translated in the mitochondrial 
matrix with the assistance of several transcription, translation and assembly nuclearly 
encoded factors (Zee and Glerum, 2006). Formation of Cox1 subunit accompanied 
with heme a biosynthesis and incorporation, as well as with copper delivery, 
corresponds to the first assembly intermediate (S1). The second intermediate (S2) is 
formed by connection of the Cox1 with little complex formed from nuclearly encoded 
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subunits IV and Va. The third intermediate (S3) contains all of the subunits except 
subunits VIa and VIIa or VIIb. Addition of the last subunits leads to the formation of 
the holoenzyme monomer (S4) (Scheme 1.) (Fontanesi et al., 2006; Nijtmans et al., 
1998; Stiburek et al., 2005; Ugalde et al., 2002).  
All the studies are showing a huge group of additional functional proteins 
involved in different stages of the assembly processes, for example in translocation 
of nuclear-encoded subunits across the mitochondrial membranes, while many of 
them are highly hydrophobic; or in the formation and insertion of heme a, as well as 
in transport and embedding of primary high cell-toxic, but for correct function 
essential, ions of copper, zinc and magnesium into the nascent enzyme complex 
(Carr and Winge, 2003). However, understanding of all the pathways is in spite of all 
research still rumbling in the yeast, the situation in mammals is even more unclear. 
Studies in mammals described several human homologs of yeast assembly factors 
(see tab.1). Closer studies show some differences in their function and behaving 
from yeast ones (Zee and Glerum, 2006). 
   
 
Tab 1. Functional classes of COX assembly factors. (Zee and Glerum, 2006) 
Assembly 
factor 
Reference Function Localization Human 
homolog 
 
Translational activators or regulators 
Pet309p (Manthey and McEwen, 
1995) 
Cox1p translation Matrix LRPPRC 
Mss51p (Barrientos et al., 2004) Regulation of Cox1p translation Matrix  
Cox14p (Barrientos et al., 2004) Regulation of Cox1p translation IMM  
Pet111p (Mulero and Fox, 1993) Cox2p translation Matrix  
Pet54p (Brown et al., 1994) Cox3p translation Matrix  
Pet122p (Brown et al., 1994) Cox3p translation Matrix  
Pet494p (Brown et al., 1994) Cox3p translation Matrix  
 
Membrane insertion 
Oxa1p (Hell et al., 1998) Insertion of charged domains  IMM OXA1 
Mba1p (Ott et al., 2006) Insertion of uncharged domains IMM  
Cox18p (Saracco and Fox, 2002)  Cox2p C-terminus insertion IMM  
Mss2p (Saracco and Fox, 2002) Cox2p C-terminus insertion IMM  
Pnt1p (Saracco and Fox, 2002) Cox2p C-terminus insertion IMM  
 
Subunit-specific chaperones 
Cox20p (Hell et al., 2000) Cox2p chaperone IMM COX20 
 
Copper insertion 
Cox17p (Glerum et al., 1996a) Copper chaperone Cytosol/IMS COX17 
Cox11p (Carr et al., 2005) Copper insertion into Cox1p IMM COX11 
Sco1p (Dickinson et al., 2000) Copper insertion into Cox2p IMM SCO1 
/SCO2 
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Heme biosynthesis 
Cox10p (Tzagoloff et al., 1993) Heme B to heme O conversion IMM COX10 
Cox15p (Barros et al., 2001) Heme O to heme A conversion IMM COX15 
 
Assembly chaperones 
Shy1p (Mashkevich et al., 1997) Subcomplex assembly IMM SURF1 
Pet100p (Church et al., 2005) Nuclear-encoded subunit 
assembly 
IMM  
 
Unknown 
Cox19p (Nobrega et al., 2002) ?  Cytosol/IMS COX19 
Cox23p (Barros et al., 2004) Copper chaperone? Cytosol/IMS COX23 
Pet117p (McEwen et al., 1993)  ? ?  
Pet191p (McEwen et al., 1993) ? ? PET191 
Cox16p (Carlson et al., 2003) ? IMM COX16 
Note: Question marks indicate that the information is unknown. 
 IMM for inner mitochondrial membrane 
 
Beside the COX well known function in coupling of the electron transfer 
between cytochrome c and molecular oxygen, and vectorial translocation of protons 
across the inner mitochondrial membrane, the previously mentioned data predicts 
CcO to play an important role in regulation of all the processes of oxidative 
phosphorylation.  
The respiratory control is generally understood as stimulated by ADP followed 
by its decrease due to conversion into ATP (Ludwig et al., 2001). This phenomenon 
could be explained by the chemiosmotic hypothesis (Mitchell, 1966).  
The second system of regulation is based on phosphorylation of CcO by 
mitochondrial (cAMP-dependent) protein kinase, which turns on the allosteric 
inhibition of CcO at high intramitochondrial ATP/ADP ratios (Ludwig et al., 2001). 
Extracellular signals that increase mitochondrial Ca2+ are suggested to activate 
mitochondrial Ca2+-dependent protein phosphatases and dephosphorylate 
cytochrome c oxidase (Kadenbach et al., 2000). 
 
Human cytochrome c oxidase in health and disease 
 
It is obvious that CcO plays irreplaceable role in the elementary process of 
cell. Just slight disruption in its structure may have devastating consequences for the 
whole process of energy supply of the cell, organ and whole organism. Mitochondrial 
diseases caused by respiratory chain disorders as mentioned previously are not as 
rare as commonly believed. Their estimated prevalence of 1 cases per 5,000 persons 
is similar or even higher to that of better known neurological diseases, such as 
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amyotrophic lateral sclerosis and the muscular dystrophies (Chinnery and Turnbull, 
2001; Schaefer et al., 2004). 
Isolated CcO deficiency, commonly named COX deficiency, represents one of 
the most frequent reasons of respiratory chain defects in humans associated with a 
wide spectrum of clinical phenotypes (Bohm et al., 2006; Shoubridge, 2001). 
Predominantly, there are affected tissues with high energetic demand, especially the 
brain, skeletal muscle and heart (DiMauro and Schon, 2003; Robinson, 2000). The 
clinical phenotype is usually severe and often fatal. As mentioned before, the therapy 
of mitochondrial diseases in general is still woefully inadequate (Zeviani and Di 
Donato, 2004) and genetic counseling with eventual prenatal diagnosis in affected 
families is complicated by several difficulties in searching for the basic cause of the 
disease. COX disorders can have one of two genetic origins: defects stemming from 
mutations in the mtDNA are either maternally inherited or sporadic, whereas defects 
encoded in the nuclear DNA will be inherited in an Mendelian fashion (Zee and 
Glerum, 2006). Only the clear understanding of basic pathogenic mechanisms based 
on a detailed characterization of COX deficiency at the protein level in various tissues 
and accompanied by molecular analyses, can enable the accurate genetic (Vesela et 
al., 2004). 
Since the first large-scale deletion in mtDNA causing mitochondrial myopathy 
was described (Holt et al., 1988), many other mutations were reported in association 
to isolated COX deficiency or COX deficiency together with decrease of another 
respiratory chain enzyme (Keightley et al., 1996; Schon et al., 1989; Zeviani and 
Carelli, 2003). But mtDNA mutations explain only a minority of human COX 
deficiencies (Shoubridge, 2001). Based on family genealogies, it is assumed that 
most of the COX defects have its origin in nuclear genes. The main interest was 
concentrated to the screening of the 10 nuclear-encoded COX subunits, but until very 
recent no mutation has been found (Barrientos et al., 2002a; Coenen et al., 2006). 
The first case was presented by Zeviani et al. at the MITOCOMBAT meeting in 
March 2008. Therefore, the most non-maternally inherited mutations for COX defects 
must occur in non-structural genes (Zee and Glerum, 2006). The past decade has 
seen the identification of mutations in 6 COX assembly factors – SURF1, SCO2, 
SCO1, COX10, COX15, and LRPPRC. 
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Leigh syndrome and SURF1  
Surf1 deficiency is the most common recognized cause of systemic 
cytochrome c oxidase deficiency. Although the biochemical defect is expressed in all 
aerobic tissues, clinical consequences are usually restricted to the function of central 
nervous system, and most patients present with Leigh disease (Head et al., 2004).  
Leigh syndrome is an early-onset progressive neurodegenerative disorder with 
a characteristic neuropathology consisting of focal, bilateral lesions in one or more 
areas of the central nervous system, including the brainstem, thalamus, basal 
ganglia, cerebellum, and spinal cord. The lesions are areas of demyelization, gliosis, 
necrosis, spongiosis, or capillary proliferation. Clinical symptoms depend on which 
areas of the central nervous system are involved, but commonly include failure to 
thrive, feeding difficulties and hypotonia. The main laboratory findings are raised 
lactate in the blood and cerebrospinal fluid, but the diagnosis is confirmed only by the 
presence of bilateral symmetrical lesions (Rahman et al., 1996). Leigh syndrome can 
result from a number of different defects in mitochondrial energy metabolism, most 
commonly deficiencies of cytochrome oxidase (COX), pyruvate dehydrogenase, 
NADH-ubiquinone oxidoreductase (Complex I) and ATP synthase. In a small number 
of cases (Oquendo et al., 2004) with Leigh syndrome and COX deficiency, mutations 
in mitochondrial DNA (mtDNA) were found and Leigh syndrome was observed in 
some patients with mutations in the COX10 and COX15 gene (Antonicka et al., 
2003a; Bugiani et al., 2005; Oquendo et al., 2004). But most of the patients with 
Leigh syndrome and cytochrome c oxidase deficiency are harbouring a mutation in 
the SURF1 gene. There were described also two cases of patients with mutation in 
SURF1 gene but without Leigh syndrome phenotype (Salviati et al., 2004; Von Kleist-
Retzow et al., 2001). 
 
SURF1 in brief: 
Acronym for: surfeit locus protein 1 
Yeast homolog: SHY1  
Human gene: 
 Position: chromosome 9q34 
 Structure: 9 exons spanning 4.7kb; on reverse strand 
 Transcript: 1037bps 
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Protein:  
 Structure: 300 residues; matured 30kD; 2 transmembrane domains  
 Localization: inner mitochondrial membrane 
 Function: unknown exactly – participate in maturation and expression of Cox1 
due to R.sphaeroides insertion of active site heme a 
Mutations: about 40 different (missense, nonsense, insertions and deletions affecting 
usually the C terminus disabling insertion of the protein to the inner 
mitochondrial membrane); 845_846delCT prevalent in Slavonic population  
Clinical phenotype: mostly classical Leigh syndrome - subacute necrotizing 
encephalomyelopathy characterized by bilaterally symmetric necrotic lesions 
in subcortical brain regions. Von Kleist-Retzow et al. 2001 and Salviati et al. 
2004 described two cases with isolated COX deficiency due to SURF1 
mutations but without typical Leigh syndrome phenotype. 
Patient prognoses: poor due to the progressive fatal course; survival 3-8 years, rarely 
more 
Described cases: many – Leigh syndrome is one of the most common disorders of 
the respiratory chain in infancy and childhood and mutations in SURF1 explain 
the molecular background in a large proportion of these patients  
(Barrientos et al., 2002b; Bohm et al., 2006; Brown and Brown, 1996; Head et al., 
2004; Mashkevich et al., 1997; Munaro et al., 1997; Pecina et al., 2003; Pequignot et 
al., 2001; Salviati et al., 2004; Stiburek et al., 2006; Tiranti et al., 1999; Tiranti et al., 
1998; Von Kleist-Retzow et al., 2001; Williams et al., 2001b; Yao and Shoubridge, 
1999; Zee and Glerum, 2006; Zhu et al., 1998) 
 
LRPPRC 
Merante in 1993 reported the results of biochemical investigations on a group 
of patients from the Saguenay-Lac-Saint-Jean region of Quebec, who had an 
unusual form of cytochrome oxidase deficiency and Leigh disease (Merante et al., 
1993). This group was distinguished from the classical presentation of COX 
deficiency with Leigh disease, by the severity of the biochemical defect in different 
tissues. The activity of COX in skin fibroblasts, amniocytes, and skeletal muscle was 
50% of normal; in brain and liver, there were very low activities, and in kidney and 
heart it was close to normal values (Merante et al., 1993). Morin in 1993 presented 
the detail clinical and metabolical report in these children (Morin et al., 1993). 
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Mootha in 2003 took up the previous studies, which marked a LRPPRC gene 
on chromosome 2p16 as a candidate gene for Leigh syndrome, French-Canadian 
type (LSFC), and in 22 patients with LSFC phenotype identified mutations. 21 of 
them carried homozygous mutation c.1119C>T in exon 9 predicting a missense 
change A354V (Mootha et al., 2003). The last patient carried this mutation on one 
allele; while on the other allele, there was 8 nucleotides deletion in exon 35 resulting 
in a premature stop codone (Mootha et al., 2003). According to their results and 
previously published data, they suggested that LRPPRC participates probably in 
mRNA processing both in the nucleus and the mitochondrion. 
 
LRPPRC in brief: 
Acronym for: leucine-rich PPR motif-containing protein 
Yeast homolog: PET309 - gene required for the stability and processing of Cox1p 
Human gene: 
 Position: chromosome 2p21-p16 
 Structure: 38 exons spanning 128.26kb; on reverse strand 
 Transcript: 5095 bps  
Protein:  
 Structure: 1394 residues; 130 kD; leucine-rich protein 
 Localization: mitochondrial matrix 
Function: unknown, lower levels associated with reduced levels of COX mRNA 
transcripts within the mitochondria 
Mutations: 21 out of 22 patients harbouring in exon 9 c.1061C>T (A354V) on both 
alleles, one patient is compound heterozygous for previous mutation and 8bp 
deletion in exon 35 
Clinical phenotype: the Saguenay-Lac.St. Jean form of COX deficient Leigh 
syndrome called also Leigh syndrome – French Canadien type (LSFC) 
presenting together with characteristic changes of Leigh syndrome in  the 
central nervous system also microvesicular steatosis, which corresponds well 
with almost absent COX activity in liver 
Patient prognoses: poor due to the progressive fatal course; survival 6 months to 6 
years, rarely up to 11 years 
(Merante et al., 1993; Mootha et al., 2003; Morin et al., 1993; Xu et al., 2004) 
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SCO protein family 
Sco (an acronym for synthesis of cytochrome c oxidase) protein family in 
humans includes Sco1 and Sco2 proteins (Paret et al., 1999). Both Sco proteins are 
highly similar, and both are required for viability. These two proteins contain a highly 
conserved CxxxC motif that presumably binds copper, and therefore is hypothesized 
to transport copper to COX (Carr and Winge, 2003; Horng et al., 2005; 
Papadopoulou et al., 1999). The structural similarity to the thioredoxin family has led 
to the proposal that Sco functions as a thiol:disulfide oxidoreductase, instead of, or in 
addition to, a copper trafficking (Chinenov, 2000). On the basis of extreme sensitivity 
to hydrogen peroxide, the Sco proteins have also been proposed to function as 
copper-dependent redox switches in signaling (Williams et al., 2005). Due to the 
latest findings, Sco proteins seem to participate also in regulation of cellular copper 
homeostasis (Leary et al., 2007). The studies in yeast (Nittis et al., 2001) have a 
limited comparative value, while even sharing great identity in the core region (Cu 
binding site) with the human Sco polypeptides (Papadopoulou et al., 1999), their 
behaving is not identical. Yeast Sco2 seems to lack the essential role in COX 
assembly, although it is able, when overexpressed, to partially rescue Sco1 mutants 
(Briere and Tzagoloff, 2007). In contrast, patients with mutation in either Sco1 or 
Sco2 present a COX deficiency that is not rescuable by the respective homolog, 
indication nonoverlapping activities of the two proteins in metallation of subunit II 
(Glerum et al., 1996b; Leary et al., 2004). To explaine the current data Leary et al 
2007 (Leary et al., 2007) proposed a model in which human Sco proteins cooperate 
on two separate aspects of copper metabolism. One is to promote maturation of the 
CuA site and the second is to regulate copper efflux under condition of excessive 
cellular copper. To date, many functional studies including structural characterization 
of human Sco2 (Banci et al., 2007a) and crystallization of yeast and human Sco1 
proteins were done(Abajian and Rosenzweig, 2006; Balatri et al., 2003; Williams et 
al., 2005), however, the precise function of Sco proteins remains unclear. 
Mutations in SCO1 causing COX deficiency were described so far only in two 
boys from one family (Valnot et al., 2000a). First boy of unrelated healthy parents 
(birth weight 2700g, length 45cm) was born hypotonic and lethargic requiring 
immediate assistance for respiratory distress. Biochemical investigation revealed 
severe metabolic acidosis with abnormally high urinary lactate, fumarate and 
succinate. Severe axial hypotonia, hypoglycemia and hyperlactatemia together with 
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liver enlargement and recurrent episodes of apnea and bradycardy were observed to 
the age of 2 months when he died. Isolated COX deficiency was found in liver and 
skeletal muscle. One year later, a second boy was born (birth weight 1750g), who 
presented severe neurological distress and metabolic acidosis and died at the age of 
5 days. Both patients were compound heterozygotes for c.363_364delGA, which 
results in a frameshift and premature codon in exon2, and c.520C>T changing a 
highly conserved praline into a leucine (P174L) (Valnot et al., 2000a) Its pathology 
was described by Banci et al (Banci et al., 2007b). And this mutant genotype was 
found to have an affect on the COX assembly (Paret et al., 2000) as well as on 
function of Cox17, another copper chaperone (Cobine et al., 2006a) 
 
Fig 4. Structure models of proteins of SCO family showing high structural similarities (pfam) 
 
 
Sco1     Sco2  
 
 
 
Mutations in SCO2 were mostly associated with fatal infantile hypertrophic 
cardiomyopathy (Jaksch et al., 2001a; Jaksch et al., 2000; Papadopoulou et al., 
1999; Sacconi et al., 2003; Salviati et al., 2002b; Sue et al., 2000). The predominant 
symptoms were muscular hypotonia, severe hypertrophic cardiomyopathy (HCM), 
encephalopathy, peripheral neuropathy and a pronounced COX deficiency in striated 
muscle and most probably in the CNS (Freisinger et al., 2004). By that time we 
published group of 7 patients, where two distinct phenotypes due to the mutation 
type were presented. One with severe hypertrophic cardiomyopathy connected with 
compound heterozygous phenotypes and the other associated with homozygozity of 
g.1541G>A mutation with a bit milder clinical manifestation missing severe 
cardiologic involvement (Vesela et al., 2004). The g.1541G>A mutation was found at 
least on one allele in all described patients, so far. Therefore it is thought to be 
prevalent. There are studies showing the biochemical benefit of copper 
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supplementation in cultured cells from patients with Sco2 mutations (Jaksch et al., 
2001b; Salviati et al., 2002a), but the progression in clinical manifestation in patients 
treated with copper was not observed (Jaksch et al., 2001a) 
 
SCO in brief: 
Acronym for: synthesis of cytochrome c oxidase 
Yeast homolog: Sco1p 
Function: Both human Sco proteins are highly similar, and both are required for 
viability. These two proteins contain a highly conserved CxxxC motif that 
presumably binds copper, thus it is hypothesized to transport copper to COX 
(Carr and Winge, 2003). The structural similarity to the thioredoxin family has 
led to the proposal that Sco functions as a thiol:disulfide oxidoreductase, 
instead of, or in addition to, a copper trafficking (Chinenov, 2000). On the 
basis of extreme sensitivity to hydrogen peroxide, it has also been proposed 
that Sco proteins function as copper-dependent redox switches in signaling 
(Williams et al., 2005). In the latest findings, Sco proteins seem to also 
participate in the regulation of cellular copper homeostasis (Leary et al., 2007). 
To date, however, the precise function of Sco proteins remains unclear. 
SCO1: 
Human gene: SCO1 (homologue 1) 
 Position: chromosome 17p13.1 
 Structure: 6 exons spanning 17.19 kb; on reverse strand 
 Transcript: 1708 bps  
Protein:  
 Structure: 301 residues; 34 kD;  
 Localization: inner mitochondrial membrane 
Mutations: 2-bp deletion, missense  
Clinical phenotype: encephalopathy, myopathy, hepatopathy and cardiomyopathy 
Patient prognoses: poor due to progressive fatal course; survival 5 days to 2 months 
(Abajian and Rosenzweig, 2006; Balatri et al., 2003; Briere and Tzagoloff, 2007; 
Dickinson et al., 2000; Horvath et al., 2000; Petruzzella et al., 1998; Valnot et al., 
2000a; Williams et al., 2005; Winge, 2003) 
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SCO2: 
Human gene: SCO2 
 Position: chromosome 22q13.33 
 Structure: 2 exons spanning 2.01kb; on reverse strand 
 Transcript: 992bps  
Protein:  
 Structure: 266 residues; 30kD;  
 Localization: inner mitochondrial membrane 
Mutations: g.1541G>A found in all patients at least on one allele; missense and short 
deletions (1 and 2bp) 
Clinical phenotype: fatal infantile hypertrophic cardiomyopathy; encephalomyopathy; 
peripheral neuropathy; spinal muscular atrophy (in two cases) 
Patient prognoses: poor due to the progressive fatal course; survival several days to 
2 years 
(Jaksch et al., 2001a; Jaksch et al., 2000; Leary et al., 2006; Papadopoulou et al., 
1999; Petruzzella et al., 1998; Salviati et al., 2002b; Sue et al., 2000; Tarnopolsky et 
al., 2004; Tay et al., 2004) 
 
Heme a synthesis 
 A heme is a metal-containing prosthetic group of several proteins, and 
consists of an iron atom embedded in a porphyrin ring system coordinated by four 
nitrogen atoms (Moraes et al., 2004). There are three biologically important forms of 
heme . types a, b, and c – which differ by modifications in the porphyrin ring. Most 
common type of heme is heme b (the prosthetic group of proteins like hemoglobin 
and myoglobin) and is also presented in the mitochondrial bc1 complex, and it is not 
covalently bound to its apoprotein partner. Heme c contains two vinyl side chains and 
is covalently bound to the protein itself (cytochrome c and c1) (Moraes et al., 2004). 
Heme a is a unique heme compound present exclusively in COX. It is synthesized 
through a catalytic pathway that takes place inside mitochondria (Fontanesi et al., 
2006). Heme a synthesized from heme b differs from that protoheme in that a methyl 
side chain is oxidized into a formyl group, and one of the vinyl side chains (on C2) is 
replaced by a isoprenoid (farnesyl) chain (Moraes et al., 2004). This process is 
catalyzed by several enzymes including products of COX10 and COX15 genes. 
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COX10  
After detail studies of Cox10p in yeast, the human ortholog (COX10) was 
cloned and described as a candidate gene for COX deficiency in man (Glerum and 
Tzagoloff, 1994). Murakami described in 1997 the genomic structure and expression 
of the human COX10 gene (Murakami et al., 1997). The gene encodes heme a 
farensyl transferase, which catalyzes the transfer of a farnesyl group to the vinyl at 
position 9 of the porphyrin ring system (Petruzzella et al., 1998). This reaction is the 
early one in the process of generation of heme a from protoheme (heme b). By the 
farnesylation of the heme b is produced heme O, the precursor molecule of heme a 
(Bugiani et al., 2005). 
The firs patient, a boy with isolated COX deficiency born to first-cousin 
parents, was found homozygous for c.612C>A transversion in exon 4 of the COX10 
gene. This transversion resulted in the change of an uncharged asparagine residue 
into a basic lysine residue (N204K). Both parents were heterozygous for the 
transversion. The boy had an unremarkable development until the age of 18 months, 
at which time he developed ataxia. At 2 years of age he presented with poor eye 
contact, severe muscle weakness, hypotonia, ataxia, ptosis, pyramidal syndrome, 
and status epilepticus. Increased urinary amino acids were suggestive of a proximal 
tubulopathy. Isolated COX deficiency in muscle, isolated lymphocytes, and cultivated 
fibroblasts was presented. He died at 2 years of age. An older sister had died at 5 
years of age of a mitochondrial encephalopathy ascribed to COX deficiency. A 
younger sister had progressive neurologic deterioration with similar biochemical 
anomalies at the age of 2 years and died at the age of 3 years (Valnot et al., 2000b). 
Three years later, Antonicka et al. 2003 (Antonicka et al., 2003a) described 
two other cases:  
A white male infant born at term, presented in the first week of life with 
hypoglycemia, metabolic acidosis, hypotonia and poor feeding. Metabolic laboratory 
evaluation showed persistent lactic acidosis, elevated plasma alanine and proline, 
and no evidence of an organic acidemia. Profound sensorineural hearing loss was 
demonstrated by brainstem evoked response testing at 2 months age. Severe 
transfusion-dependent macrocytic anemia developed by 3 months. He was 
hospitalized with acute episodes of dehydration, metabolic acidosis and hypotension 
complicated by anemia. Cardiovascular evaluation revealed severe biventricular 
hypertrophic cardiomyopathy at age 4 months. Diagnostic muscle biopsy showed 
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normal structural histology but severely reduced or absent COX staining in most 
fibers. COX activity measured in mitochondria isolated from frozen muscle was less 
than 5% of control values; activities of all other respiratory chain enzymes were 
normal. He died at the age of 5 months. Molecular analyzes revealed  c.791C> A 
transversion in exon 4, and a c.878C>T transition in exon 5 of the COX10 gene, 
predicting amino acid substitutions at T196K and P225L (Antonicka et al., 2003a). 
The second patient, a girl, was the third child of healthy, non-consanguinous 
parents. Her development stopped suddenly after one and a half months and she 
presented with hypotrophy, transfusion-dependent anemia, slight splenomegaly, 
severe hypotonia and high lactate/pyruvate levels in both blood and CSF. MRI 
analysis showed severe symmetrical lesions typical for the Leigh syndrome. She died 
at the age of 4 months due to a central respiratory failure. COX activity in a muscle 
biopsy was decreased to 16% of the lowest control values and in fibroblasts down to 
18%, while the other respiratory enzymes activities were normal. The patient was 
heterozygous for two missense mutations in exon 7, an c.1211A>T transversion and 
an c.1211A>G transition, predicting two different amino acid substitutions at the 
same evolutionarily conserved site in the protein: D336V and D336G (Antonicka et 
al., 2003a). 
 Last patient was described in 2004 by Coenen et al. (Coenen et al., 2004). 
The boy patient was born at term as the first child of consanguineous parents. At the 
age of 5 months, he developed progressive failure to thrive, and pronounced motor 
agitation was noted. Gross motor development was severely delayed at 7 months 
together with generalized muscular hypotonia with persistent head lag at traction, 
ataxia, hypermetria, exaggerated tendon reflexes with enlarged reflex zones, low 
amplitude nystagmus, and saccadic eye movements. Ocular fixation was weak. He 
was not able to grasp. Laboratory evaluation showed metabolic acidosis with 
elevated serum and cerebrospinal fluid lactate concentrations. Magnetic resonance 
imaging of the brain showed a pattern comparable to Leigh-like disease. Biochemical 
COX activity was significantly reduced in muscle and fibroblasts. The boy died at 9 
months of age during acute respiratory infection due to cardiorespiratory failure 
(Coenen et al., 2004).  
 
COX10 in brief: 
Yeast homolog: Cox10p 
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Human gene: 
 Position: chromosome 17p12-p11.2 
 Structure: 7 exons spanning 139.27kb; on forward strand 
 Transcript: 2993bps 
Protein:  
 Structure: 443 residues; 49kD 
Protein family and names: protoheme IX farnesyltransferase, mitochondrial 
precursor; heme O synthase; heme a farnesyltransferase 
 Localization: inner mitochondrial membrane 
Function: catalyzing of the farnesylation of a vinyl group at position C2 
resulting in the conversion of protoheme (heme b) to heme O 
Mutations: 6 different at 4 patients described so far 
Clinical phenotype: progressive mitochondrial encephalopathy, proximal renal 
tubulopathy, Leigh-like syndrome, fatal infantile hypertophic cardiomyopathy, 
transfusiondependent anemia 
Patient prognoses: poor due to the progressive fatal course; survival from 5 months 
to 5 years 
(Antonicka et al., 2003a; Coenen et al., 2004; Glerum and Tzagoloff, 1994; Valnot et 
al., 2000b)  
 
COX15 
Studies on yeast mutants indicate that COX15 is part of a three component 
mono-oxygenase, catalyzing the hydroxylation of the methyl group at position 8 of 
heme O, the precursor molecule of heme a. Heme O is the product of the 
farnesylation of protoheme, a reaction catalyzed by COX10. The alcohol group 
added to heme O is then oxidized into the corresponding aldehyde by an unknown 
enzyme, to produce heme a (Bugiani et al., 2005). The human COX15 has two splice 
variants (COX15.1 and COX15.2 [GenBank accession numbers NM_078470 and 
NM_004376]) that differ in the predicted C-terminal amino acid sequence and 3´UTR 
(Antonicka et al., 2003b), but the functional role of the two isoforms remains to be 
established (Petruzzella et al., 1998). 
The first patient with cytochrome c oxidase deficiency due to mutations in the 
COX15 was described in 2003 (Antonicka et al., 2003b). This patient developed soon 
after birth muscle hypotonia, epilepsy, and lactic acidosis, but the clinical course was 
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dominated by the development of a rapidly fatal hypertrophic cardiomyopathy. The 
patient died at the age of 24 days. The COX residual activity was markedly reduced 
in heart tissue (6%) and was low (25–30%) in liver, kidney, and cultured fibroblasts 
but normal in skeletal muscle. The child was a compound heterozygote with a 
missense mutation (c.700C>T, R217W) in exon 5 on one allele and a splice site 
mutation (c.447-3C>G) in intron 3 on the other allele, resulting in the deletion of exon 
4 (Antonicka et al., 2003b). 
Oquendo 2004 (Oquendo et al., 2004) reported the same c.700>RT missense 
mutation (R217W) in a homozygous form in a child with rapidly progressive Leigh 
syndrome and chronic gastrointestinal dysfunction. The first symptoms of the disease 
(hypotony, feeding difficulties and horizontal nystagmus) manifested at the age of 7 
months. Sequentially, other symptoms were following – motor regression, 
progressive microcephaly and retinopathy. Magnetic resonance imaging of the brain 
at 1 year of age showed bilateral lesions in several regions compatible with a 
diagnosis of Leigh syndrome. He died at 4 years of age due to pneumonia. COX 
activity measured spectrophotometricaly in fibroblasts was under the detection level 
(Oquendo et al., 2004). 
Last case, published so far, presents a patient with feeding difficulties and 
failure to thrive from the first days of life. Subsequently, he developed psychomotor 
delay, hypotonia, muscle weakness, cerebellar tremor, and eye movement 
incoordination. MRI at 18 months of age diagnosed the Leigh syndrome. The 
symptoms slowly worsened thereafter with virtual body growth arrest, progressive 
loss of postural control. At the age of 4 years the MRI showed mild progression of the 
described changes, and in spite of unchanged clinical features, the plasma lactate 
and pyruvate previously markedly elevated decreased to normal levels. Apart from 
the central nervous system and skeletal muscle, the patient showed no abnormality 
in other tissues or organs. The boy was 16 years old and living in the time of the 
literature report. Biochemical assays showed an isolated COX deficiency both in 
skeletal Muscle and cultured fibroblasts (42% and 22% residual activity compared to 
the mean of controls, respectively). As a cause of his disease, there were found two 
novel heterozygous mutations in COX15 gene. The first mutation, a 503C>G 
transversion, introduces a premature stop codon in exon 4 (H152X). The second 
mutation, a 1081T>C missense transition in exon 8, results in a serine (highly 
conserved at this position among the species) to proline substitution at amino acid 
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position 344, in the C-terminal end of the fifth predicted transmembrane domain of 
the protein (Bugiani et al., 2005). 
 
COX15 in brief: 
Yeast homolog: Cox15p 
Human gene: 
 Position: chromosome 10q24 
 Structure: 9 exons spanning 20.82kb; on reverse strand 
 Transcript: 4588bps 
Protein:  
Structure: 410 residues; 46kD; 2 isoforms varying in C termini (COX15.1 and 
COX15.2); 5 transmembrane domains; mitochondrial targeting 
sequence 
 Localization: inner mitochondrial membrane 
Function: involved in catalyzing the hydroxylation of the methyl group at position 8 of 
heme O, the precursor molecule of heme a 
Mutations: 3 different missense; one splicing mutation 
Clinical phenotype: 3 cases so far, each with different phenotype: hypertrophic 
cardiomyopathy; rapidly fatal Leigh Syndrome; Leigh syndrome surviving at 16 
years of age 
Patient prognoses: poor due to the progressive fatal course; survival 23 days up to 
second decade 
(Antonicka et al., 2003b; Bugiani et al., 2005; Oquendo et al., 2004; Petruzzella et al., 
1998) 
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AIMS OF THE PRESENTED WORK 
 
The laboratory for study of mitochondrial disorders works as a diagnostic 
center for patients from Czech and Slovak republics. During the last years, there 
were found over 40 children with isolated COX deficiency. Mutations in SURF1 were 
found in 12 of them ((Bohm et al., 2006; Pecina et al., 2003) and unpublished cases).  
Even the adequate treatment is unknown, the understanding of the illness 
causes is important not only for the physicians but as well for the families. The 
genetic counseling was offered to these families harbouring SURF1 mutations and 
several of them embrace the possibility of prenatal diagnostics. 
Molecular background of the other cases was remaining unknown. Due to the 
possible dual origin of the defect with different hereditary aspects, the genetic 
counseling in the affected families was complicated and prenatal diagnostics very 
problematical if even possible. Previous experience leaded us to the decision to 
continue with searching for the molecular background in the remaining patients. This 
aim had to help not only with genetic counseling, but also in better treatment due to 
the better understanding of the etiology of the disease as well as to bring more 
information to clarify the metabolic processes in the context of cell energy generation. 
  
 The specific aims of this work were: 
1. to select candidate genes for the  screening in patients with biochemically 
confirmed COX deficiency 
2. to optimize suitable methods for analyses 
3. to search selected genes for mutations in the group of our COX deficient 
patients 
4. to study the pathology of found mutations  
5. to establishing of the screening methods to the routine diagnostic and bringing 
the possibility of the genetic counseling and relevant prenatal diagnostics 
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MATERIAL ANS METHODS 
 
Ethics 
 
The presented studies were carried out in accordance with the Declaration of 
Helsinki of the World Medical Association, and were approved by the Committees of 
Medical Ethics at Faculty of Medicine, Charles University and General Faculty 
Hospital in Praha. Informed parental consent, in accordance with guidelines of the 
participating institutions, was obtained. 
 
Ad 1) to select candidate genes for our screening 
 
Based on world published research data, we decided to screen the genes for 
COX assembly proteins with already described cases – both genes of the SCO 
protein family (SCO2 and SCO1) and COX10. Later, in 2003, after the first published 
case, we added also COX15 gene. We collected all available clinical and biochemical 
data of published patients and according to them we selected candidate patients with 
similar phenotype to analyze the certain gen. 
The criteria were for: 
o “SCO2 group”: isolated COX deficiency, lactic acidosis, rapid course of the 
disease, hypertrophic cardiomyopathy, encephalopathy, hypotony, respiratory 
failure, and life-span up to 2 years  
o “SCO1 group”: isolated COX deficiency, lactic acidosis, rapid course of the 
disease, hypotony, cardiological and liver involvement, and life-span up to 1 
year 
o “COX10 group”: progressive mitochondrial encephalopathy, proximal renal 
tubulopathy, and a life-span up to 2 years; later also Leigh-like syndrome, 
fatal infantile hypertophic cardiomyopathy 
o “COX15 group”: at first - hypertrophic cardiomyopathy with several months 
surviving; later also rapidly fatal Leigh Syndrome; Leigh syndrome surviving 
and longer life-span 
 
All groups were dynamic, due to the new patients and due to the literature news. 
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Ad 2) to optimize suitable methods 
 
Molecular genetic methods 
 
DNA isolation 
As a material, patients DNA isolated from peripheral blood or from cultivated 
fibroblasts were used. Rarely, in case of no other choice, DNA was isolated from 
available tissue obtained at autopsy (skeletal muscle, brain, liver or heart tissue).  
DNA isolation from peripheral blood was performed by common high-salt 
precipitation method. In case of small amount of blood and for isolation from other 
tissues, the QIAamp DNA Mini Kit (QIAGEN) was used, and all the isolation 
processes were performed according to the recommended manufacturer protocols. 
 
Polymerase chain reaction 
 
The primers were designed to the intronic regions surrounding the exons to be 
able to analyze also the neighboring regions of the coding sequences to avoid 
missing of splicing-site mutations. To the 5´end of the specific primers, sequence of a 
universal primer was added. So, all the specific sequencing reactions could be 
performed just with two universal primers (one forward and one reverse). Primer 
sequences used in our study are collected in tab.2 
The amplification of searched fragments by polymerase chain reaction was 
optimized as well as the amplification of the sequencing reaction with the universal 
primers according to the needs of the sequencing analyzer. Optimizing and all 
amplifications were performed on MJ Research Thermal Cyclers.  
To be able to confirm two mutations in SCO2 gene, the restriction side had to 
be created. We used semi-nested PCR with a specific mismatch primer. As a 
template, we used PCR product of the first PCR, which amplified the specific 
fragment and than using one of the first-PCR-primer and a mismatch primer we 
performed second PCR. The mismatch primers were designed to create a specific 
restriction site for specific restriction enzyme to distinguish fragments with and 
without mutation by single RFLP analysis. 
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Tab.2 Primer sequences 
Fragment exons included  forward primer   5’ →3’ end reverse primer   5’ →3’ end 
universal primer  “RP” caggaaacagctatgac  
universal primer  “T7”  aatacgactcactatag 
SCO2  NCBI - AF177385 
fr1  1st part of 2nd nt 1080 - nt 1098 nt 1386 - nt 1405 
fr2  2nd part of 2nd nt 1355 - nt 1375 nt 1778 - nt 1801 
fr3 3rd part of 2nd nt 1523 - nt 1543 nt 1979 - nt 1999 
Mismatch primer “1518delA” nt 1487 - nt 1516; 1515C>G  
Mismatch primer “1541 G>A”  nt 1543 - nt 1568; 1546G>T 
SCO1  NCBI - NT_010718 
fr1 1st  RP+ nt 20 - nt 39 nt 414 - nt 433 
fr2 2nd  nt 1589 - nt 1608 nt 1873 - nt 1894 
fr3 3rd  nt 4530 - nt 4549 nt 4841 - nt 4860 
fr4 4th  nt 5541 - nt 5560 nt 5815 - nt 5834 
fr5 5th  nt 10668 - nt 10688 nt 10878 - nt 10894 
fr6 6th  nt 16288 - nt 16303 nt 16579 - nt 16595 
COX10  NCBI - NC_000017 
fr1 1st  nt 51 - nt 70 nt 402 - nt 421 
fr2 2nd  nt 4841 - nt 4860 nt 5090 - nt 5111 
fr3 3rd  nt 7244 - nt 7266 nt 7761 - nt 7787 
fr4 4th  nt 32664 - nt 32673 nt 33000 - nt 33021 
fr5 5th  nt 90345 - nt 90365 nt 90693 - nt 90713 
fr6 6th  nt 122565 - nt 122585 nt 122852 - nt 122870 
fr7a 1st part of 7th nt 137287 - nt 137304 nt 137653 - nt 137672 
fr7b 2nd part of 7th  nt 137402 - nt 137418 nt 137974 - nt 137993 
COX15  NCBI - NT_030059 
fr1 1st  nt 20446 - nt 20465 nt 20617 - nt 20636 
fr2 2nd  nt 17932 - nt 17949 nt 18432 - nt 18450 
fr3 3rd  nt 15817 - nt 15835 nt 16280 - nt 16298 
fr4 4th  nt 15481 - nt 15500 nt 15732 - nt 15751 
fr5 5th  nt 12287 - nt 12304 nt 12791 - nt 12806 
fr6 6th  nt 9405 - nt 9423 nt 9824 - nt 9833 
fr7 7th  nt 6705 - nt 6725 nt 7252 - nt 7269 
fr8 8th  nt 4724 - nt 4744 nt 5179 - nt 5197 
fr9a 9.1  nt 3108 - nt 3124 nt 3348 - nt 3366 
fr9b 9.2 nt 1884 - nt 1901 nt 2230 - nt 2248 
 
PCR conditions and exact chemicals used for PCR in detail: 
PCR elements: 
1. self mix: 
a) KlenTaq polymerase (Gene Age Technologies, Czech Republic), stock concentration: 
5units/ul 
b) pC2 buffer (Gene Age Technologies, Czech Republic- 50mM Tris, pH9,1; 16mM amonium 
sulphate; 3,5mM MgCl2; 150 µg/ml BSA), stock concentration: 10x 
c) Taq polymerase - (Sigma; product No.: D6670), stock concentration: 5units/ul  
d) dNTP - Deoxynucleotide Mix (Sigma; product No.: D 7295), stock concentration: 10mM; 
working concentration: 2mM 
e) DMSO - Dimethyl sulphoxide (Sigma; product No.: D 2650) 
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f) MgCl2 solution - (Sigma; product No.: M8787); stock concentration: 25mM 
g) Primers - commercially synthesized according our sequence by Generi-Biotech company 
(working concentration 10pmol/ul) 
2. commercially available kit: 
a) Combi PPP Master Mix (Taq-Purple DNA Polymerase PCR Master Mix with MgCl and 
monoclonal antibody anti-Taq); Top-Bio s.r.o.; product No.: P-126) 
 
SCO2: 
 
All 3 fragments: 
PCR reaction mixture:                                        PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
PC2 buffer 1x  1. initial denaturation 94°C 2´ 
dNTP 0,2mM  2. denaturation 94°C 30´´ 
DMSO 6%  3. annealing 65,4°C 30´´ 
primer forward 0,4µM  4. extension 72°C 1´ 
primer reverse 0,4µM  5. 28 times repeating steps 2 to 4 
Klen Taq 
polymerase 1,5 U  6. denaturation 94°C 1´ 
gDNA 50-100ng  7. annealing 65,4°C 30´´ 
   8. extension 72°C 3´ 
 
 
Seminested-PCR: 
PCR of 2nd fragment for RFLP of g.1518delA using instead forward primer the delFm  
and for RFLP of g. 1541G>A instead of reverse primer the Bm one 
 
PCR reaction mixture:                                              PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
PC2 buffer 1x  1. initial denaturation 95°C 2´ 
dNTP 0,2mM  2. denaturation 95°C 30´´ 
MgCl2 1,175mM  3. annealing 54,6°C 15´´ 
primer forward 0,4µM  4. extension 72°C 40´´ 
primer reverse 0,4µM  5. 30 times repeating steps 2 to 4 
Taq polymerase 1,5 U  6. final extension 72°C 7´ 
PCR product fr2 5µl      
 
 
SCO1 
 
PCR reaction mixture:                                              PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
PC2 buffer 1x  1. initial denaturation 95°C 2´ 
dNTP 0,2mM  2. denaturation 95°C 30´´ 
DMSO *  3. annealing ** 30´´ 
primer forward 0,4µM  4. extension 72°C 1´ 
primer reverse 0,4µM  5. 32 times repeating steps 2 to 4 
Klen Taq 
polymerase 0,5 U  6. denaturation 95°C 1´ 
gDNA 50-100ng  7. annealing ** 30´´ 
* fr1 – 7%; fr4 – 6%; fr5 – 6%; fr6 – 10%  8. extension 72°C 3´ 
   ** fr1, 3, 4, 6 = 57,3°C; fr2 = 53°C; fr5 = 54,4°C 
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COX10 
 
All fragments excluding fr2: 
PCR reaction mixture:                                              PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
PC2 buffer 1x  1. initial denaturation 95°C 2´ 
dNTP 0,2mM  2. denaturation 95°C 30´´ 
DMSO *  3. annealing ** 30´´ 
primer forward 0,6µM  4. extension 72°C 1´ 
primer reverse 0,6µM  5. 32 times repeating steps 2 to 4 
Klen Taq 
polymerase 0,5 U  6. denaturation 95°C 1´ 
gDNA 50-100ng  7. annealing ** 30´´ 
* fr6 = 2%; fr7a = 6%; fr7b = 2%  8. extension 72°C 3´ 
   ** fr1, 7a, 7b = 60,6°C; fr3, 4, 5, 6 = 58,4°C 
 
 
Fragment 2: 
PCR reaction mixture:                                              PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
PC2 buffer 1x  1. initial denaturation 95°C 2´ 
dNTP 0,2mM  2. denaturation 95°C 30´´ 
MgCl2 1,175mM  3. annealing 54°C 20´´ 
primer forward 0,6µM  4. extension 72°C 40´´ 
primer reverse 0,6µM  5. 30 times repeating steps 2 to 4 
Taq polymerase 1,5 U  6. final extension 72°C 7´ 
PCR product 5µl      
 
 
 
COX15 
 
All fragments excluding fr2: 
PCR reaction mixture:                                               PCR conditions: 
element final concentration in 1 reaction (25µl)   Step Temperature Time 
CombiPPPMaster Mix 1x  1. initial denaturation 95°C 2´ 
DMSO *  2. denaturation 95°C 30´´ 
primer forward 0,4µM  3. annealing * 30´´ 
primer reverse 0,4µM  4. extension 72°C 1´ 
gDNA 50-100ng  5. 28 times repeating steps 2 to 4   
* fr8 = 4%   6. denaturation 95°C 1´ 
   7. annealing * 30´´ 
   8. extension 72°C 3´ 
   **fr7= 64,8°C; all others = 59,5°C 
 
 
Purification of PCR products 
Amplified PCR products were extracted from the agarose gel (Sigma) and 
purified by gel extraction using QIAquick Gel Extraction Kit (QIAGEN) or Wizard SV 
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Gel and PCR Clean-Up System (Promega). All steps were performed according to 
the recommended manufacturer protocols. The gel extraction method turned out to 
have better results for sequencing analyzes than direct PCR products cleaning. 
 
Sequencing 
The first part of samples, most of the fragments screened for mutations in 
SCO2, was sequenced by gel automated cycle sequencing analyzer AlfExpress 
(Amersham Pharmacia Biotech) using AmpliTaq polymerase (Applied Biosystems) 
and RP, T7 universal cy5-labelled primers. The mixture for sequencing reaction 
contained 1xpC2 buffer; 4,8mM MgCl2; AmpliTaq polymerase according to the 
manufacturer; 0,3mM dNTPs containing 7-deaza-dGTP (Amersham Biosciences); 
2,4µM ddNTPs; 0,14µMof cy5-labelled primer and 75ng of PCR template. The 
fragments for sequencing were prepared in steps see tab 3. 
 
Tab 3. PCR conditions for sequencing 
 
 Step Temperature Time 
1. initial denaturation 95°C 5´ 
2. denaturation 95°C 5´´ 
3. annealing 50°C 25´´ 
4. extension 68°C 50´´ 
5. 35 times repeating steps 2 to 4 
 
 
Later a new capillary instrument, the ABI PRISM 3100-Avant Genetic Analyzer 
from Applied Biosystems, was available in the laboratory and the sequencing 
process was optimized for the new instrument. It simplified and speeded up the 
process, so most of SCO1, COX10 and COX15 fragments were analyzed on this 
new instrument. For the sequencing PCR reaction was used the chemistry of Big Dye 
Terminator v.3.1 Cycle Sequencing  Kit according to the manufacturer protocol with 
slide modification in mixture. We used to the 20 µl of total reaction amount instead of 
8 µl of commercial mixture kit only 2 µl and the buffer conditions were kept by adding 
of 3 µl of Big Dye Terminator v.1.1; 3.1 5x Sequencing Buffer (Applied Biosystems). 
3,2 pmol of primer and concentration of template according to the recommended 
amounts, as well as the PCR conditions were kept due to the manufacturer protocols. 
Cleaning of sequencing reaction was carried out according to the recommended 
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ethanol precipitation protocols. For final denaturation, the Hi-Di Formamid (Applied 
Biosystems) was used in the amount of 20 µl per reaction. To guarantee perfect 
denaturation of all sequenced DNA regions, the ready reaction mixture dissolved in 
20 µl of Hi-Di Formamide was denaturated by heating up to 95 °C for 3 minutes. For 
the sequencing the 50 cm or 80 cm capillary (Applied Biosystems) was used. 
The obtained data were analyzed manually, later than by SeqScape Software 
v2.5 (AppliedBiosystems). 
 
RFLP analyses 
 Found mutations were verified by a relevant PCR RFLP (restriction fragment 
length polymorphism) method (tab.4) according to the manufacturer protocols to 
each restriction endonuclease (buffer conditions, amount and temperature). The 
same method was later used also for screening of controls in the cases of novel (not 
described) mutations.  
 
Tab 4. RFLP analysis 
mutation restriction endonuclease PCR fragment used  for analyses notes 
SCO2    
g.1182G>C. Eco88I (Fermentas) Fr. 1 Wild type - 0cut; mutated - 1cut 
g.1280C>T BfaI (BioLabs) Fr. 1 Wild type - 0 cut; mutated - 1cut 
g.1518delA MaeIII (Roche) Fr. 2 + Nested PCR with mismatch primer “1518delA” Wild type - 2 cuts; mutated - 1cut 
g.1541G>A HindIII (Fermentas) Fr. 2 + Nested PCR with mismatch primer “1541 G>A” Wild type - 0 cut; mutated - 1cut 
g.1756A>C EcoO109 (Fermentas) Fr. 2 Wild type - 1cut; mutated - 0cut 
COX10    
c.184A>T MaeIII (Roche) Fr. 3 Wild type - 1cut; mutated - 0cut 
c.476G>A TaqI (Fermentas) Fr. 3 Wild type - 1cut; mutated - 0cut 
c.1291C>T Eco52I (Fermentas) Fr. 7b Wild type - 1cut; mutated - 0cut 
SCO1    
c.394G>A HpaII (BioLabs) Fr. 3 Wild type -0cut; mutated - 1cut 
 
 
Biochemical methods*
 
Cell cultures and tissues 
All studied tissues (blood, skeletal and heart muscle, liver, brain, kidney) and 
primary fibroblast cultures were obtained from three patients harbouring two different 
combinations of SCO2 mutations, three patients carrying mutations in SURF1 and 
                                                 
* these analyses were performed in collaboration with L. Stibůrek 
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age-related controls. Primary skin fibroblast cultures were established from forearm 
skin biopsy. Open muscle biopsies were obtained from the tibialis anterior muscle 
and were frozen at −80◦C. Post-mortem heart, liver, brain (basal ganglia) and kidney 
tissue specimens were removed and frozen less than 2 h after death.  
 
Isolation of mitoplasts and mitochondria 
Skeletal muscle, brain, heart and kidney mitochondria were isolated according 
to standard differential centrifugation procedures (Rickwood D, 1987) in a buffer 
comprising 150 mM KCl, 10 mM Tris/HCl, 2 mM EDTA and 2 µg/ml aprotinin (pH 7.4) 
at 4°C. Liver mitochondria were isolated in a buffer comprising 250 mM sucrose, 20 
mM Tris/HCl, 2 mM EDTA and 2 µg/ml aprotinin (pH 7.4) at 4°C. Mitoplast-enriched 
fractions were prepared from cultured fibroblasts using digitonin (Sigma–Aldrich) as 
described in (Klement et al., 1995), with a final digitonin/protein ratio of 0.6 mg/mg. 
Protein concentrations were determined with the Bio-Rad Protein Assay kit (Bio-Rad 
Laboratories). All samples were stored at −80°C. 
 
Enzyme activity assays 
Activities of COX and CS (citrate synthase) were measured 
spectrophotometrically in fibroblasts and isolated tissue mitochondria essentially as 
described in (Rustin et al., 1994). 
 
Electrophoresis 
BN-PAGE (Blue Native PAGE) (Schagger and von Jagow, 1991)  was used 
for separation of mitochondrial membrane protein complexes on polyacrylamide 8–
15, 8–16 and 10–18% (w/v) gradient gels using a Mini Protean® 3 System (Bio-Rad 
Laboratories). Mitoplasts or mitochondria were solubilized with DDM (n-dodecyl β-D-
maltoside; Sigma–Aldrich) with a final DDM/protein ratio of 1.0 mg/mg in a buffer 
containing 1.5 M aminocaproic acid, 2 mM EDTA and 50 mM Bis-Tris (pH 7.0) at 
4°C. Serva Blue G (Serva) was added to solubilized protein at a concentration of 0.1 
mg/mg of detergent, and 5–50 µg of protein was loaded for each lane. The 
electrophoresis was performed at 40 V, 4°C for 1 h and then at 100 V, 4°C. Tricine 
SDS/PAGE was carried out under standard conditions with 12% polyacrylamide, 
0.1% (w/v) SDS and 5.5 M urea gels. Mitochondrial fractions were dissociated in 50 
mM Tris/HCl (pH 6.8), 12% (v/v) glycerol, 4% SDS, 2% (v/v) 2-mercaptoethanol and 
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0.01%(w/v) Bromophenol Blue for 30 min at 37°C, and approx. 10 µg of protein was 
loaded for each lane. For two-dimensional BN/SDS/PAGE (Schagger and von 
Jagow, 1991), strips of the first-dimension gels were incubated for 40 min in 1% 2-
mercaptoethanol and 1% SDS and then for 10 min in 1% SDS, and denatured 
proteins were then resolved in the second dimension on 13% polyacrylamide, 
0.1%SDS and 5.5 M urea gels (Schagger and von Jagow, 1991; Williams et al., 
2003).  
 
Polyclonal antibody raised against human SCO2 
A Sco2-specific antibody was generated by injecting rabbits with a synthetic 
peptide specific for the C-terminal part of human Sco2 
(CGRSRSAEQISDSVRRHMAAF). Testing of the specificity of the Sco2 antiserum 
revealed that affinity purification was not required, and crude serum was used in all 
subsequent experiments. 
 
Immunoblot analysis 
Proteins were electroblotted from the gels on to ImmobilonTM-P PVDF 
membranes (Millipore) using semi-dry transfer for 2 h at a constant current of 0.8 
mA/cm2. Membranes were air-dried overnight, rinsed twice with 100% (v/v) methanol 
and blocked in PBS and 10%(w/v) non-fat dried milk for 1 h. Primary detection was 
performed with mouse monoclonal antibodies raised against COX subunits COX1 (A-
6403; 1 µg/ml), COX2 (A-6404; 1 µg/ ml), COX4 (A-21348; 2 µg/ml), COX5A (A-
21363; 2 µg/ml) and COX6B (A-21366; 1 µg/ml) (Molecular Probes), with rabbit 
polyclonal antiserum raised against human SCO2 (1:1000) and with monoclonal 
antibodies raised against the flavoprotein subunit of SDH (succinate:ubiquinone 
oxidoreductase) (A-11142; 0.1 µg/ml) (Molecular Probes) and the VDAC(voltage-
dependent anion channel) (31HL Ab-1; 1.4 µg/ml) (Calbiochem) at indicated dilutions. 
Blots were incubated with primary antibodies in PBS, 0.3% (v/v) Tween 20 and 1% 
non-fat dried milk for 2 h. Secondary detection was carried out with goat anti-mouse 
IgG– horseradish peroxidase conjugate (A8924; 1:1000) (Sigma– Aldrich) or with 
goat anti-rabbit IgG–horseradish peroxidase conjugate (A0545; 1:2000) (Sigma–
Aldrich) in PBS, 0.1% Tween 20 and 1% non-fat dried milk for 1 h. The blots were 
developed with West Pico Chemiluminescent substrate (Pierce) and exposed to 
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Kodak BioMax Light films (Kodak). The films were subsequently scanned and digital 
images were analyzed using the Quantity One application (Bio-Rad Laboratories).  
 
Structural and histological studies – methods**
 
Material 
The formalin-fixed and frozen tissues were collected from autopsies carried 
out in several pathology departments. In rare cases, biopsy samples were available. 
The samples were embedded in paraffin for histology. For electron microscopy the 
samples were embedded in Epon – Araldite mixture – and examined using a Jeol 
100B microscope. Frozen samples were preferred for biochemistry.  
 
Histochemistry 
Cryostat sections 10 µm (for COX histochemistry) or 5 µm (for histochemistry 
of other respiratory chain enzymes) prepared from frozen tissues were stained for 
COX, succinate dehydrogenase (SDH) and NADH-tetrazolium reductase (NADH-TR) 
activity using standard laboratory methods (Lojda et al., 1979).  
 
Immunohistochemistry 
Mouse IgG1 anti-prohibitin antibody (LabVision, Fremont, CA USA) and 
mouse IgG1 anti-mitochondrial antigen antibody (MU213-UC, clone 113-1, Biogenex, 
San Ramon, CA, USA) working well in paraffin-embedded sections after antigen 
retrieval (10 mM citrate buffer, pH 7.6, for 3x5 min in a microwave 750 W) were used 
for staining mitochondria. Primary antibodies were incubated overnight at 4°C, diluted 
1:500 and 1:100, respectively. They were detected using a DAKO EnVisionπTM 
Peroxidase Mouse kit (DAKO, Glostrup, Denmark) with 3,3´-diaminobenzidine as 
substrate. 
 
                                                 
** these analyses were performed in collaboration with H. Hůlková at Institute of Inherited Metabolic 
Disorders, 1st Faculty of medicine, Charles University and General University Hospital, Praha 
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RESULTS AND DISCUSSION  
 
 
Ad 3) to search selected genes for mutations in the group of our patients with 
isolated COX deficiency  
 
SCO2 gene 
35 patients were screened. Pathological mutations were found in 8 of them. 
Six children were homozygous and their parents were heterozygous for the missense 
mutation g.1541G>A that exchanges glutamate for lysine at the position 140 of the 
amino acid chain (E140K). The patient seven is compound heterozygous for 
mutations g.1541G>A, and g.1280C>T which results in a stop codon replacing 
glutamine at position 53 (Q53X). This patient inherited the g.1541G>A mutation from 
his mother; no DNA was available from his father. In addition, the first five patients 
are also homozygous, while patient seven is heterozygous, in the SCO2 gene for the 
polymorphism g.1182G>C and the silent mutation g.1756A>C. Last found patient is 
heterozygous for the g.1541G>A and a novel deletion 1518delA causing the frame 
shift. The protein is then affected at the 132nd amino acid by one base frameshift 
resulting in the disappearance of the most important Sco2-protein part, the Cu-
binding motive at position 133-137. First six cases were published by Vesela et al. 
2004. Last two cases are not published yet.  
 
SCO1 gene  
Screening of 14 candidates revealed one patient with homozygous mutation 
c.394G>A in 3rd exon of SCO1 gene. This mutation changes glycine at the position 
132 to serine. Parental samples are not available. This mutation was not present in 
200 healthy controls (Vesela, Stiburek et al. 2008, manuscript in preparation). 
 
COX10 and COX15 
 Among 24 patients for screening of COX10, and 22 patients for screening of 
COX15 we did not find any harbouring pathological mutation. In COX10 we found 3 
novel nucleotide exchanges (Tab. 5) 
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Tab. 5 Found novel polymorphisms in COX10 gene 
number of patients % of healthy controls nucleotide 
exchange 
amino acid 
exchange heterozygous homozygous heterozygous homozygous
c.184A>T T64S 3 0 17 0 
c.476G>A R159Q 10 7 61 18 
c.1291C>T R131W 1 0 9 0 
 
 
Ad 4) to study the pathology of found mutations  
 
SCO1 gene 
In one case, it was found guanine > adenine nucleotide transition at the 
position 394 of the SCO1 cDNA.  
The girl was born at the 39th week of gestation with a birth weight of 2200 g 
and length 46 cm. She was classified as a hypotrophic newborn with a tendency to 
hypoglycemia. Progressive hypotony and psychomotor retardation were developing 
since early postnatal period. Echocardiography at the age of 5 months revealed 
progressive hypertrophy of left ventricle and a sonography revealed atrophy of 
central nervous system. Liver enlargement and biochemical investigation at the age 
of 6 month indicated hepatopathy. She died due to cardiac failure at the age of 6 
months. In comparison with the only published patients (Valnot et al., 2000a), the 
clinical symptoms are relatively similar except the progressive cardiological 
involvement. The published patient has no evidence of cardiological involvement 
except episodes of bradycardy. The reason for differences between the described 
case and our patient may be in shorter live span of 2 months, while the hypertrophy 
at our patient was recognized at the age of 5 months. The liver enlargement was not 
observed at our patient till the age of 6 month; the published patient showed this 
symptom four months earlier.  
Dominant laboratory finding was severe lactic acidemia (fasting lactate 3.61 
mmol/l, normal value <2.3 mmol/l) with even higher postprandial level (7.72 mmol/l). 
The urinary organic acid profile showed elevated excretion of 2-oxoglutarate (1150 
mg/g creatinine, normal value <200 mg/g creatinine), lactic acid (103 mg/g creatinine, 
normal value <60 mg/g creatinine) and other Krebs cycle intermediates (fumaric acid 
185-193 mg/g creatinine, normal values <15 mg/g creatinine, malate 75 mg/g 
creatinine, normal value <15 mg/g creatinine). Mild ketonuria (3-hydroxybutyric acid 
107 mg/g creatinine, normal value <100 mg/g creatinine) and dicarboxylic aciduria 
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(due to MCT oil administration) was also found. These findings including the elevated 
Krebs cycle intermediates correspond to the published data (Valnot et al., 2000a).  
The activity of COX was markedly low in isolated muscle mitochondria 
obtained from a muscle biopsy at the age of 6 months (11,42 nmol/min/mg protein, 
reference range of age related controls 25-120 nmol/min/mg protein). The activity of 
citrate synthase, the control enzyme, was normal. 
The mutation changes glycine at the position 132 of the amino acid chain to 
serine. According to the multispecies alignment (Fig.2), it is clear that guanine as well 
as glycine at that position is highly conserved. 200 healthy controls were examined 
and the mutation was not present at any allele. The pathology of this mutation can be 
explained due to its localization: region among leucine 108 and isoleucine 131 is 
described as an important for dimerization of functional Sco1 protein (Leary et al., 
2004). Replacement of nonpolar glycine at the closely contiguous position 132 by 
serine with the uncharged but polar side chain may have influence on the stability of 
the dimer itself.  
 
Fig.2 Genomic sequence alignment (Ensembl) of the specific region 
 
Source: Homo sapiens chromosome:NCBI36:17 part of 3rd exon of SCO1 gene; Bos taurus 
chromosome:Btau_3.1:19; Gallus gallus chromosome:WASHUC2:18; Macaca mulatta 
chromosome:MMUL_1:16; Monodelphis domestica chromosome:BROADO5:2; Pan troglodytes 
chromosome:CHIMP2.1:17; Mus musculus chromosome:NCBIM37:11; Rattus norvegicus 
chromosome:RGSC3.4:10; Drosophila melanogaster CG8885.2L; Caenorhabditis elegans C01F1.2 II; 
Saccharomyces cerevisiae YBR037C II 
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SCO2 gene 
 
Genotype - phenotype correlation 
 
The mutation g.1280C>T was described previously in literature (Papadopoulou 
et al., 1999). This transition is creating a premature stop codon at level of glutamine 
53 (Q53X).  
A novel one base deletion at the position 1518 leads to the frame shift. The 
protein is affected from the 132nd amino acid, and it results in vanishing of the most 
important part of the Sco2 protein, the Cu-binding motive CxxxC at position 133-137. 
If the affected sequence would be translated, the newly synthesized protein would 
miss the Cu-binding motive, which seems to be crucial for its function, and would be 
shorter due to the hypothetical premature stop codon (Fig.3). 
 
Fig 3. The possible effect of deletion g.1518delA. 
 
1st row – part of the cDNA sequence of SCO2 gene (affected base in red; Cu-binding motif in blue) 
2nd row appropriate translation 
3rd row hypothetical translation after the deletion of the 1518 base (in green) 
 
Transition g.1541G>A cause replacement of glutamic acid by lysine at the 
position 140 of the amino acid chain. Banci et al. 2007 (Banci et al., 2007a) explains 
its pathogenity based on structural characterization of the Sco2 protein: “Glu140, 
located in helix α1 and essentially not solvent exposed, is involved in a salt bridge 
with Lys143, which is disrupted in the Glu140Lys mutant. In addition, the introduction 
of a longer side chain in a buried region could locally destabilize side-chain packing 
between helix α1 and the facing β sheet. Because Glu140 is relatively close to the 
copper binding Cys137, the possible structural rearrangements induced by the 
mutation could affect both the copper binding properties and protein stability, factors 
which both influence protein function, thus possibly rationalizing at the molecular 
level the mutant misfunction.” (Banci et al., 2007a). For better illustration see Fig.5. 
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Fig.5 Structure of human Cu(I) Sco2 (Banci et al., 2007a) 
On the left side, the average structure of the lowest-energy ensemble is shown. The metal binding 
residues Cys133 and Cys137 are shown in yellow, and His224 is shown in blue. The copper(I) ion 
is depicted as a pink sphere.  
On the right, the superimposition of 30 lower-energy structures of Cu(I)HSco2 is represented as a tube 
whose radius is proportional to backbone rmsd. α helices and β strands are colored in red and 
cyan, respectively. 
 
 
 
 
 
The clinical data of our patients with mutations in the SCO2 gene are 
summarized in Tab.6. 
 
Tab. 6 Clinical data in eight children with isolated COX deficiency and mutations in the SCO2 gene 
 
Patient Onset of symptoms 
Inspiratory 
stridor 
Infantile 
encephalopathy Hypotonia HCMP* Brain atrophy 
Respiratory** 
insufficiency 
Age at 
death 
1. 3 mo ++ ++ ++ - microcephaly last 2 mo 8 mo 
2. 6 wk - ++ ++ -/+ ? last 2 mo 12 mo 
3. 4 mo ++ ++ ++ - ++ last mo 15 mo 
4. 6 mo + ++ + - ++ last mo 8 mo 
5. 5 mo - ++ hypertony - ++ last mo 9 mo 
group 
A 
6. 3 mo - ++ ++ -/+ ++ since 6th mo alive*** 
7. birth - ++ + ++ ++ since birth 7 wk group 
B 8. birth? ++ ? ++ ++ ++ since birth? 3 mo 
* HCMP: hypertrophic cardiomyopathy.       
** artificial ventilation in an intensive care unit.      
*** last information at the age of 7 mo      
  
SCO2 mutations are commonly associated with fatal infantile hypertrophic 
cardio-encephalo-myopathy. Looking at the clinical data of our patients (tab 6), who 
represent the biggest group of patients with mutations in SCO2 gene published so 
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far, it brought us to deeper study of ours and literature findings. We found out, that 
the patients with SCO2 mutations can be divided into two subgroups due to their 
phenotype, which surprisingly very well corresponds with their genotypes. 
First group (group A) represents patients harbouring the homozygous state of 
the prevalent mutation E140K (g.1541G>A). Group A include six of our patients 
(Patient 1 to 6; P1 – P6) and three published cases (Jaksch et al., 2001a).  
The second group (group B) includes patients with heterozygous form of 
E140K combined with another mutation. The second group is composed of patient 7 
(P7; g.1280C>T), patient 8 (P8; g.1518delA) and all other published cases (Jaksch et 
al., 2000; Leary et al., 2006; Papadopoulou et al., 1999; Sacconi et al., 2003; Salviati 
et al., 2002b; Sue et al., 2000; Tarnopolsky et al., 2004; Tay et al., 2004)  
Various polymorphism and silent mutations were described in the SCO2 gene 
(Jaksch et al., 2000; Jaksch et al., 2001b; Papadopoulou et al., 1999). Our patients 
from group A were all homozygous, and patients from group B heterozygous for the 
polymorphism g.1182G>C and the silent mutation g.1756A>C in the SCO2 gene.  
The first clinical symptoms of the disease in group A occurred early in the 
neonatal period, but compare to the first symptoms manifested in group B, there 
were delayed.  
The common findings in group B are encephalopathy and fatal hypertrophic 
cardiomyopathy with early onset in the neonatal period leading to death within the 
first 3 month of life.  
In contrast, all children in group A had the early postnatal adaptation 
uneventful. The first clinical symptoms including progressive infantile encephalopathy 
with muscle weakness and respiratory distress developed between 3rd and 10th 
month of age. All of them died between 8 and 18 month of age due to respiratory 
failure. No hypertrophic cardiomyopathy was present in our patients, and the onset of 
cardiomyopathy in patients described in the literature was delayed after the age of 8–
18 months (Jaksch et al., 2001a).  
Two patients in literature (Salviati et al., 2002b; Tarnopolsky et al., 2004) and 
our patients P6 and P8 were also classified as Werdnig-Hoffmann disease - like 
phenotype, but all patients were unsuccessfully investigated for mutation in the SMAI 
gene before the diagnosis of COX deficiency was acknowledged.  
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On neuroimaging using CT and/or MRI, severe cortical atrophy was found in 
all children from both groups, but the typical necrotic lesions in the basal ganglia 
associated with Leigh syndrome were never observed. 
Among the common laboratory findings belong increased levels of lactate and 
alanine in both blood and cerebrospinal fluid. COX activities were decreased in the 
skeletal muscle tissues, but the activities measured in cultivated fibroblasts were 
about normal. That is in contrast to the patients with Leigh syndrome due to 
mutations in the SURF1 gene, where COX deficiency is observed also in cultivated 
fibroblasts.  
Our observations were published in original paper Vesela et al. 2004. The 
patient (P6) was diagnosed in April 2008 and the data are collected to be published 
soon (Klement et al., 2008, manuscript in preparation).  
Although the clinical course of the disease may depend on the type of 
mutation in the SCO2 gene, the prognosis is unfavorable in all affected children. 
Functional consequences of SCO2 mutations are still poorly understood, but they are 
related to changes in the amount and composition of COX molecules in different 
cells.  
There were available a few frozen samples of different types of tissue from our 
patients with isolated COX deficiency due to SCO2 mutations. It opened new 
possibilities of further studying of pathological consequences in different tissues on 
biochemical and histochemical levels, which were described in original articles and 
presented at the international conferences (Stiburek et al., 2005).  
 
Biochemical studies 
Samples harbouring mutations in SCO2 were available from P2, P5 – both 
group A (homozygous for g.1541G>A) - and P7 representing group B (g.1280C>T / 
g.1541G>A). While there was not enough material of different tissues to perform all 
the measurements in each of both SCO2 groups and then to obtain relevant 
comparable results, we decided to moderate the aim and compare the findings to the 
results obtained from samples with COX deficiency due to mutations in SURF1 gene 
as well.  
There were chosen relevant samples of three patients with SURF1 mutations. 
For better orientation, we marked them as patient 9-11. Patient 9 (P9) was a 
compound heterozygote for the combined frame shift deletion-insertion mutation in 
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SURF1 c.312_321del 311_ 312insAT, resulting in the formation of a premature 
termination codon, and a c.821_839del18 deletion in SURF1 leading to highly 
unstable mRNA (Williams et al., 2001a). Patient 10 (P10) was homozygous for the 
frame shift deletion c.845_846delCT leading to the formation of a premature 
termination codon, and patient 11 (P11) was homozygous for a c.688C>T nonsense 
substitution in SURF1 leading to the formation of a premature termination codon 
truncating the protein at Arg230 (Pecina et al., 2003). 
 
Activities of COX in SCO2 and SURF1 patient tissues 
To determine the residual COX activity of the mitochondrial preparations, we 
expressed COX activity relative to the activity of the mitochondrial marker enzyme, 
citrate synthase (CS). COX/CS ratio presents values of COX activity normalized to 
CS activity as a percentage of the mean reference range. Severe isolated defects of 
COX activity were found in the SCO2 patient heart (8-34% COX/CS), skeletal muscle 
(19-28%) and brain (13-18%), whereas in cultivated fibroblasts (62-100%) and liver 
(64-100%) the activity was in reference range or border low. There were no 
significant differences between the SCO2 groups A and B. In contrast, severe 
reduction of COX activity was found in all of our SURF1 fibroblast cultures (6-14% 
COX/CS) (Tab.7). 
 
Tab.7 COX activity in various tissues of SCO2 patients P2, P5, P7 and SURF1 patients P9–P11 
 
 P2 P5 P7 P9 P10 P11 
Tissue COX/CS activity (%) 
Heart 8 34 30 n.d. n.d. n.d. 
Muscle 19 28 21 11 22 9 
Brain 16 18 13 20 n.d. n.d. 
Liver 76 64 100 n.d. n.d. n.d. 
Fibroblasts 62 82 100 12 6 14 
 
Values of COX activity normalized to CS activity are expressed as a percentage of the mean reference range (COX/CS activity). 
n.d., not determined. 
 
 
Steady-state levels of COX holoenzyme in SCO2 and SURF1 patient tissues 
All mitochondrial preparations used in the present study were balanced on the 
basis of the immunoblot signal of the mitochondrial inner membrane protein complex 
SDH. To determine the residual steady-state levels of COX holoenzyme in tissues of 
patients as a percentage of control values, dilutions of control mitochondria were 
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loaded on the same gels. Mitochondrial samples were resolved using BN-PAGE and 
subsequently probed with an anti-COX1 antibody. In heart mitochondria from patients 
P2, P5, P7 and P9, the steady-state levels of COX holoenzyme were found to be 
approx. 25, 30, 10 and 40% of control values respectively (Fig.6A and 6B). 
Mitochondria from basal ganglia of patients P2, P5, P7 and P9 contained approx. 20 
and 15% of residual holoenzyme respectively (Fig.6C). In skeletal muscle from 
patients P2, P5, P10 and P11, the holoenzyme levels were approx. 10, 20, 15 and 
10% of control values respectively (Fig.6D). In primary fibroblasts, the steady-state 
levels of COX holoenzyme were found to be approx. 70% of control values in the 
case of patients P2 and P5, approx. 60% in the case of patient P7 (Fig.6E) and 
approx. 15% in the case of patients P10 and P11. The liver samples of SCO2 
patients (P2, P5, P7) were the least affected and contained similar steady-state 
levels of COX holoenzyme to control samples, whereas in SURF1 patient liver (P9) 
the holoenzyme was found to be approx. 80% of control values (Fig.6F). The only 
slight difference between group A and B might be seen in the steady-state levels of 
COX holoenzyme in the sample of heart mitochondria, where there is more profound 
decrease in the patient from group B. 
 
Fig.6 Steady-state levels of COX holoenzyme and subcomplexes in tissues and fibroblast cultures of 
SCO2 and SURF1 patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial fractions from SCO2 (P2, P5, P7) and 
SURF1 (P9–P11) patient samples were resolved by BN-
PAGE (8–15% polyacrylamide), electroblotted on to PVDF 
membranes and probed with monoclonal antibodies 
specific for subunits COX1 (A, C–F) or COX5A (B). The 
amount of protein loaded per lane (∼5 µg) was normalized 
to SDH. Three aliquots of control mitochondria 
corresponding to indicated dilutions of control samples 
were loaded on the same gels. Immunoreactive material 
was visualized by chemiluminescence. The positions of 
COX holoenzyme (a), COX subcomplexes (b–f) and 
molecular-mass standards (kDa) are indicated. 
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 Subcomplexes of COX in SCO2 and SURF1 patient tissues 
Mitochondrial preparations from various SCO2 and SURF1 patient tissues, 
primary fibroblast cultures and control samples were resolved using either BN-PAGE 
or two-dimensional BN/SDS/PAGE and subsequently probed with anti-COX subunit-
specific monoclonal antibodies in order to detect the presence and possible 
accumulation of COX subcomplexes and to uncover their subunit composition. In 
addition to holoenzyme complex (Fig.6A and 8A, complex a), heart samples of SCO2 
patients contained eight distinct COX subcomplexes (b–i). Prolonged exposure of the 
blots revealed the presence of six of them (b–f and i) also in control heart samples 
(Fig.7B and 8A). Subcomplexes c–i were found in SCO2 heart samples at highly 
accumulated levels, whereas only subcomplexes b and f were found slightly 
increased in the heart of the SURF1 patient (Fig.6A). Mitochondria from SCO2 
skeletal muscle contained increased levels of seven distinct subcomplexes (Fig.8C, 
c–i), apparently identical with that found in SCO2 patient heart. Their steady-state 
levels were, however, found to be substantially lower in this tissue (Fig.6D), and their 
full detection thus required higher protein loads (∼50 µg) and longer exposure times 
(Fig.8C). In line with this, control heart samples contained substantially higher 
steady-state levels of COX subcomplexes than skeletal muscle controls (Fig.7B and 
7C). Also, SCO2 brain samples revealed accumulated COX subcomplexes of approx. 
10–120 kDa, detectable mainly with anti-COX1 and anti-COX5A antibodies, but their 
profile differed from that found in SCO2 heart and skeletal muscle mitochondria 
(Fig.8A-C). In particular, the COX4 signal in the brain was very weak in this region. In 
contrast with SCO2 patient samples, we did not detect any accumulated 
subcomplexes in SURF1 patient brain (Fig.6C). In skeletal muscle of SURF1 
patients, we found substantially decreased levels of subcomplex b and faint 
accumulation of subcomplexes with similar electrophoretic mobility to subcomplexes 
c–f from SCO2 samples (Fig.7C). Mitochondria from SCO2 patient kidney contained 
moderately increased subcomplexes with migration similar to subcomplexes c–f and i 
from SCO2 patient heart (Fig.8D). We did not detect any conclusive accumulation of 
COX subcomplexes in SCO2 patient fibroblasts (Fig.6E and 8E). Alignment of 
parallel run immunoblots probed with different antibodies indicated, together with 
immunoblots of two-dimensional native/denaturing gels, that subcomplex b consists 
of at least COX1, COX2, COX4, COX5A and COX6B. Subcomplex c comprised at 
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least subunits COX1, COX4 and COX5A, whereas subcomplexes d–f were 
recognized solely with an anti-COX1 antibody (Fig.6-8). Subcomplex g was 
detectable with both anti-COX4 and anti-COX5A antibodies, whereas subcomplexes 
h and i were recognized only with single anti- COX4 and anti-COX5A antibodies 
respectively (Fig.8A-C). Low-molecular-mass subcomplexes g–i were not detectable 
on immunoblots of one-dimensional native gels, since the polyacrylamide gradient 
used (8–15%) was optimal for fractionation of subcomplexes b–f, while lower-
molecular-mass polypeptides were allowed to migrate out of the gel. 
 
Fig.7 COX subcomplexes in control heart, heart of SCO2 patients and skeletal muscle of SURF1 
patients 
 
 
 
 
 
 
Mitochondrial fractions from SCO2 patient heart (P2, P5 
and P7) (A, B), SURF1 patient skeletal muscle (P10 and 
P11) (C) and control samples were resolved by BN-PAGE 
(8–15% polyacrylamide), electroblotted on to PVDF 
membranes and probed with monoclonal antibodies 
specific for subunits COX1 or COX5A. The amount of 
protein loaded per lane (∼5 µg) was normalized to SDH. 
Immunoreactive material was visualized by 
chemiluminescence. The positions of COX holoenzyme (a) 
and COX subcomplexes (b–f) and the molecular-mass 
standards (kDa) are indicated. 
 
Fig.8 Subunit composition of COX subcomplexes in various tissues of the SCO2 patient P2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mitochondrial fractions (10–50 µg) from various tissues of 
SCO2 patient P2 and control samples were resolved using 
two-dimensional BN/SDS/PAGE, electroblotted on to 
PVDF membranes and probed simultaneously with 
monoclonal antibodies specific for subunits COX1, COX2, 
COX4 and COX5A. Sample loads and exposures of films 
to the blots were chosen such that the signals 
corresponding to holoenzyme complex a were of similar 
intensitieswithin both kontrol and patient immunoblots. 
Immunoreactive material was visualized by 
chemiluminescence. The polyacrylamide gradient used in 
the first dimension (BN) was 8–16% for (A, B) and 10–
18% for (C–E). The positions of COX holoenzyme (a) and 
COX subcomplexes (b–i) and the migration of molecular-
mass standards (kDa) are indicated. 
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 Steady-state levels of SCO2 protein in various tissues of SCO2 patients 
Mitochondrial fractions and fibroblast lysates were resolved using SDS/PAGE 
and subsequently probed with polyclonal antiserum raised against human SCO2. 
Equal loading was verified with an antibody raised against the mitochondrial outer 
membrane protein VDAC. The SCO2 protein was undetectable in all SCO2 brain 
samples and in heart of patients P5 and P7. In heart of patient P2 and liver of 
patients P2 and P7, the levels of mutant Sco2 were approx. 5% of control values. In 
fibroblasts of patients P2, P5, P7 the residual Sco2 was approx. 20% of control 
values, while in liver of patient P5 it was approx. 10% of control values. 
Although both Sco2 and Surf1 proteins are thought to act at a similar stage of 
COX assembly, patients carrying mutations in respective genes present with distinct 
clinical phenotypes. Quantitative immunoblot analysis of native gels revealed tissue-
specific COX assembly defects in all patients studied that corresponded to the 
enzyme activity measurements. The steady-state levels of mutant Sco2 protein were 
found severely reduced in all the probed SCO2 patient tissues. The subunit 
composition of COX subcomplexes identified demonstrates the involvement of 
human SCO2 protein in biogenesis or maintenance of COX2. 
The COX holoenzyme was repeatedly shown to be reduced to approx. 15% in 
SURF1 patient fibroblasts. Although skeletal-muscle samples of our SURF1 patients 
revealed a similar decrease in COX holoenzyme to cultured fibroblasts, SURF1-
deficient heart and liver contained substantially higher levels of residual holoenzyme. 
In contrast, the tissue-specific consequences of SCO2 mutations, mainly the 
profound difference between the residual COX activity in skeletal muscle and 
fibroblasts. 
We show that despite very low levels of mutant protein the livers of SCO2 
patients display practically no reduction of fully assembled COX, corresponding to 
high residual activity. 
The precise molecular basis of tissue-specific consequences of SCO2 and 
SURF1 mutations remains unresolved. In addition to different levels of COX 
holoenzyme, variable levels of subcomplexes were found among different tissues, 
although some of them displayed the same residual level of the holoenzyme (e.g. 
heart and muscle). This is likely to be attributable to different rates of clearance of 
partially assembled or unassembled subunits. The tissue-specific pattern of 
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assembly defects only partially overlaps with the expression of particular tissue-
specific isoforms of COX subunits, suggesting the involvement of a rather different 
mechanism. In our patients, the mutant Sco2 protein was almost undetectable in 
brain and heart with profound COX deficiency, whereas the liver, and particularly 
fibroblasts, contained small but significant amounts of residual Sco2. However, we 
find it unlikely that this minor difference could account for the distinct biochemical and 
clinical involvement of these tissues, unless there is a pronounced difference in 
‘spare capacity’ of Sco2 for copper delivery to the CuA centre in these tissues. 
Therefore we speculate that tissue-specific consequences of SCO2 and SURF1 
mutations, in terms of both holoenzyme and subcomplex levels, suggest the 
existence of tissue-specific functional differences of these proteins that may have 
evolved to meet different requirements for the regulation of COX biogenesis. 
 
Structural and histochemical studies 
 
Patient samples for these studies were divided into two groups due to the 
mutation type in SCO2 gene. Group A represents tissues of patients harbouring the 
homozygous state of the prevalent mutation E140K (g.1541G>A). Group B collects 
samples with heterozygous form of E140K combined with other mutation (g.1280C>T 
or g.1518delA) (Vesela et al., 2008). 
Some of them were available for histochemical analysis (Tab. 8). 
 
Tab. 8 List of tissues available for analysis 
 
 Group A phenotype Group B phenotype 
 Siblings  Siblings   
 Patient 2 Patient3 Patient 5  Patient 1  Patient 1b  Patient 7 Patient 8 
 male female female  male  male  male  female 
 12 mo death 15 mo death 9 mo death  8 mo death  not known  7 wk death  11wk death 
CNSa  P/F  P  P/F  P  0  P/F  P  
 
BC+HC  
 
BC+HC    BC   
Regions of  
CNS  
C, Bg,  
CRBL,  
brain stem,  
MS  
CRBL,  
MS  
C, Bg,  
CRBL*,  
brain stem  
C, Th, Bg,  
CRBL,  
brain stem  
 C, MS  Bg  
Peripheral  0  0  0  0  EM  0  EM  
nerveb      skin nerve   sural nerve  
Skeletal 
muscle  F  F+EM  F  P  F  P/F  P/F+EM  
a/b BC+HC  BC+HC  BC+HC   BC  BC  BC+HC  
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Hearta  P/F  0  P/F  P  0  P/F + EM  P  
 BC+HC   BC+HC    BC   
Liver a/b  P/F+EM  0  P/F  P  0  P/F  F  
 BC+HC   BC+HC   BC  BC+HC  
Other 
tissues  Kidney  0  Kidney  0  0  Retina  0  
 P/F (HC)   P/F (HC)    P   
Abbreviations: CNS, central nervous system; C brain cortex; Th, thalamus; Bg, basal ganglia; CRBL, cerebellum; MS, spinal  
medulla; F, frozen tissues; P, formalin-fixed paraffin-embedded tissues; EM, biopsy for electron microscopy; BC, COX de- 
ficiency proven biochemically; HC, COX deficiency confirmed histochemically. 0 tissues not available.  
*Dentate nucleus was available only in this case.  
Patient 1b is a brother of patient 1, who were not investigated in any other studies only in structural and histochemical. 
 
Central and the peripheral nervous systems 
In both groups there were regressive changes characterized by shrinkage of 
neurons and neuronal depopulation accompanied by gliosis and variable 
neocapillarization. The changes were expressed with different intensity in the areas 
examined (for sample availability in individual cases see Tab.8). Maximal neuronal 
depletion was focally expressed in the cerebellar cortex affecting both granular and 
Purkinje cell layers, associated with marked Bergman astrogliosis. Severe neuronal 
degeneration and astrogliosis were also seen in the dentate nucleus (available in one 
case only). High degree neocapillarization accompanied by loss of individual cells 
was present in basal ganglia in both groups. Necrosis of the type seen in Leigh 
syndrome (Powers and DeVivo, 2002) was not observed. In other parts of the brain 
(cortex, thalamus and brain stem), there was only patchy loss of neurons. The spinal 
medulla motoneurons were moderately affected in both groups. The number of 
mitochondria was not generally increased, with the exception of large striatal neurons 
and some spinal motoneurons, the perikarya of which harboured numerous fine 
eosinophilic granules strongly stained with both antimitochondrial antibodies. COX 
activity was also uniformly decreased in both samples available for histochemistry. 
Neuronal involvement is non-specific in terms of morphology. It is widespread 
throughout the central nervous system and corresponds to the category of 
polioencephalopathy described in mitochondrial disorders (Powers and DeVivo, 
2002). Structural changes in the nervous system were developed in both groups, in 
spite of shorter average survival of patients in group B.  
The sample of retina was available in one patient from B group. There was 
pronounced shrinkage and loss of neurons restricted to the ganglion cell layer, 
whereas the number of neurons in both outer and inner nuclear layers was not 
significantly altered. There were large eosinophilic granular aggregates strongly 
stained for mitochondria in the retinal photoreceptors. They were concentrated 
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between the photoreceptor inner and outer segments. Discrete aggregates were 
seen in neurits in the external plexiform layer.  
Ultrastructural analysis of peripheral nerves, realized in two patients (one of 
each phenotype group, Tab.8), showed axonal degeneration and demyelinization. 
The sural nerve from the compound heterozygous patient also showed signs of 
remyelinization and axonal sprouting in spite of the shorter course of disease in this 
case. No mitochondrial abnormalities were observed. 
Here we show for the first time that affection of retinal neurons may be an 
integral part of the neuropathology in COX deficiency due to SCO2 mutations. The 
ultrastructure of the mitochondrial aggregates in the zone of photoreceptors could not 
be evaluated for technical reasons. To the best of our knowledge there is no 
evidence of similar mitochondrial alteration in mitochondrial retinopathies studies 
(McKechnie et al., 1985). Alterations of peripheral nerves suggest the presence of 
peripheral neuropathy also involving sensitive fibers (sural nerve). Our pathological 
findings (sensitive neuropathy, retinopathy) exceed the range of clinical 
symptomatology. 
 
Skeletal muscle and the skeletal muscle involvement 
The spectrum of findings in tissues from the patients of group A ranged from 
relatively mild structural changes (atrophy of individual fibres, both angulated and 
rounded, occasional fibre hypertrophy and rare muscle fibre destruction) to fully 
developed neurogenic atrophy. The histochemistry showed irregular decrease in 
COX activity in samples of three patients (Tab.8). In all of them, both SDH and 
NADH-TR were highly active, without having a regular normal checkerboard pattern. 
Groups of atrophic angulated fibres displayed typical enhanced activities of both 
dehydrogenases. In one case in group B (death at 11 weeks), signs of neurogenic 
atrophy were combined with myopathic changes (marked hypertrophy of muscle 
fibres in comparison to age-matched samples, frequent internalized nuclei, variation 
in fibre size). COX activity was not detectable histochemically. In the second case 
(death at 7 weeks), the pathology was limited to increased variation in fibre size with 
occasional enlarged rounded fibres. Ragged red fibres and ultrastructural 
mitochondrial abnormalities were absent in both groups. 
With regard to spinal motoneuron degeneration and COX deficiency in muscle 
fibres proven histochemically and biochemically, we explain the skeletal muscle 
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pathology as a consequence of ‘‘double hit’’ – neurogenic lesion and metabolic 
affection. The range of structural alterations in our patients may be caused by 
differences in skeletal muscle sampling, which may not match lesions of the spinal 
motoneurons. Isolated decrease in COX activity secondary to neurogenic muscle 
atrophy is not likely, as it is associated with decrease in the activity of other 
respiratory chain enzymes, including SDH (Berger et al., 2003). 
 
Heart and the cardiac involvement 
The histology showed no signs of cardiac hypertrophy in group A and only 
moderate multiplication of mitochondria without increase in their size, demonstrable 
by specific staining. COX activity tested histochemically was found to be uniformly 
decreased (samples from two cases available). In group B there was marked cardiac 
concentric hypertrophy of both ventricles with three and four-fold increase in weight 
against age-matched controls. The histology showed hypertrophy of cardiocytes with 
enlarged hyperchromatic and often doubled nuclei. Mitochondria were increased in 
number and many of them were significantly enlarged. Ultrastructurally they were 
frequently aggregated densely with very close contacts of their external membranes. 
In smaller mitochondria, the cristae were short and condensed. In larger 
mitochondria (4–5 mm in diameter) the cristae were loosened, longer and unevenly 
oriented. Some of them were tubular; others were narrow, densified, linear and rigid. 
Single or several lucent intramitochondrial vacuoles (lipid? glycogen?) with marked 
tendency to fusion were sometimes seen. Crystalloid formations were absent. 
Profound COX deficiency could be confirmed biochemically in one case (patient 7). 
The cardiac involvement due to hypertrophic cardiomyopathy was linked to 
compound heterozygosity for E140K and a nonsense mutation, and was responsible 
for the severe, rapidly progressive clinical course. No significant cardiac involvement 
was apparent in our patients homozygous for E140K. 
 
Kidney  
Samples were available from two patients of group A. The histology was 
normal, without any significant increase in the number of mitochondria. Strong 
histochemical activity of COX was comparable with controls.  
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Liver 
There was neither hepatomegaly nor increase in the number of mitochondria 
in the histology of available samples from patients of group A. In two cases there was 
microvesicular steatosis. In one of them it was associated with increase in the 
amount of glycogen. In the third case the histology was normal. Liver biopsy 
available in one case showed no abnormalities of the mitochondrial ultrastructure. In 
group B there was centrolobular venostasis associated with necrosis of individual 
hepatocytes and discrete intracellular cholestasis (patient 7). Microvesicular steatosis 
was seen in patient 8. In two samples (patients 2 and 8) there was a questionable 
decrease in histochemically detectable COX activity, corresponding to the 
biochemical results. 
So no obvious disease-specific structural alterations were detectable with the 
exception of borderline decrease in COX activity in some cases. Alteration of the liver 
parenchyma in group B is most probably secondary to venostasis due to prolong 
heart failure before death of the investigated patients. These findings together with 
the absence of any pathology in the kidney correspond well with the clinical and 
biochemical data. Although Sco2 protein is expressed in all tissues ubiquitously 
(Horng et al., 2005), the phenotype resulting from SCO2 mutations shows decreased 
COX activity and affliction in certain tissues only; these mutations cause 
encephalocardiomyopathy (Jaksch et al., 2000; Leary et al., 2006; Papadopoulou et 
al., 1999; Sacconi et al., 2003; Salviati et al., 2002a; Sue et al., 2000; Tarnopolsky et 
al., 2004; Tay et al., 2004). The reason for the tissue sensitivity and specificity is not 
clearly understood so far. 
 
In terms of pathology the structural phenotype of COX deficiency due to 
mutations in SCO2 in the studied set of patients can be characterized as 
neuromuscular disorder with two subvariants differing in the degree of cardiac 
involvement. 
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CONCLUSIONS 
 
 Clinical course of the isolated cytochrome c oxidase deficiency is very 
heterogenous. The results of our studies enabled: 
 
o better understanding of biochemical and functional impact of nuclearly 
encoded assembling proteins on biogenesis of cytochrome c oxidase 
o better understanding of cytochrome c oxidase deficiency manifestation in 
morphology and function of the cells 
o better understanding of natural course of the disease in patients with 
nuclearly encoded isolated cytochrome c oxidase deficiency 
o appropriate genetic counseling and eventual prenatal diagnostics in the 
affected families  
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ABBREVIATIONS 
 
 
ADP adenosine diphosphate 
ATP adenosine triphosphate 
BN-PAGE blue native polyacrylamide gel electrophoresis 
bp base pair 
BSA bovine serum albumin 
c. coding 
cAMP cyclic adenosine monophosphate 
cDNA coding DNA 
CNS central nervous system 
COX, CcO cytochrome c oxidase 
Cox1; COX I; CO I cytochrome c oxidase subunit 1 
COX10 cytochrome c oxidase assembling gene 10 
COX15 cytochrome c oxidase assembling gene 15 
Cox2; COX II; CO II cytochrome c oxidase subunit 2 
Cox3; COX III; CO III cytochrome c oxidase subunit 3 
CS citrate synthase 
CSF cerebrospinal fluid 
CT computer tomography 
Cyt c cytochrome c 
DDM n-dodecyl -D-maltoside 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleoside triphosphate 
ddNTP dideoxynucleoside triphosphate 
EDTA ethylene diamine tetraacetic acid 
FAD+ and FADH2   flavinadenine dinucleotide (reduced and oxidized forms) 
g. genomic 
gDNA genomic DNA 
GDP guanosine diphosphate 
GTP guanosine triphosphate 
LRPPRC leucine-rich PPR motiv containing protein 
MRI magnetic resonance imaging 
mtDNA mitochondrial DNA 
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NAD+ and NADH+H+ nicotinamid adenine dinucleotide (reduced and oxidized forms) 
NADH-TR NADH tetrazolium reductase 
nDNA nuclear DNA 
OXPHOS oxidative phosphorylation system 
PBS phosphate buffer saline 
PCR polymerase chain reaction 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
SCO; SCO1; SCO2 syntase of cytochrome c oxidase; protein/gene 1; protein/gene 2 
SDH succinate dehydrogenase 
SDS sodium dodecyl sulphate 
SDS/PAGE sodium dodecylsulphate polyacrylamide gel electrophoresis 
SMA I spinal muscular atrophy type I 
SURF1 surfei locus protein 1 
TIM translocase of the outer membrane 
TOM translocase of the inner membrane 
UTR untranslated region 
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